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Introduction
The worldwide prevalence of obesity is sharply increasing and obesity has become 
one of the greatest global health challenges of the 21th century. The World Health 
Organisation reports that about 50% of European citizens are overweight and 20-23% are 
obese. (1) Obesity predisposes to many disorders, including type 2 diabetes mellitus.
 Obesity is one of the most common acquired risk factors for the development of 
insulin resistance. As a consequence of the obesity epidemic, the global prevalence 
of diabetes mellitus has increased from 153 million in 1980 to about 382 million 
affected people in 2014. (2) Age-standardized adult diabetes prevalence increased 
to 9.8% for men and 9.2% for women in 2008. (3) 
Diagnosis and classification of diabetes mellitus
Diabetes mellitus is a group of disorders characterized by hyperglycemia. The 
American Diabetes Association defines diabetes mellitus as the presence of plasma 
glucose levels higher than 11.1 mmol/l, randomly measured or 2 hours after an oral 
glucose tolerance test using 75 grams of glucose, or a fasting glucose higher than 
7.0 mmol/l. Normal values are substantially lower. Some individuals display glucose 
levels above normal but not fulfilling the criteria for diabetes mellitus. Patients with a 
fasting glucose level between 5.6 and 7.0 mmol/l have impaired fasting glucose. 
Patients with a glucose level between 7.8 and 11.1, 2 hours after ingestion of 75 grams 
glucose, are categorized as impaired glucose tolerance. (4) Together, this group of 
disorders is sometimes also listed as prediabetes. 
 Once diabetes has been diagnosed, the disease can be classified in different 
groups. The vast majority of cases can be divided in two categories. Patients with 
type 1 diabetes mellitus have an absolute deficiency of insulin due to (auto-immune 
mediated) beta-cell destruction. Patients diagnosed with type 2 diabetes mellitus 
have a combination of insulin resistance and an insufficient insulin production to 
compensate for the insulin resistance that can ultimately progress to beta cell failure.
Obesity and insulin resistance 
Although both obesity and type 2 diabetes mellitus are associated with insulin 
resistance, most obese individuals do not develop diabetes mellitus, or only after 
many years. In first instance, beta-cells will produce more insulin to overcome 
decreased insulin sensitivity. As long as the beta-cells are able to compensate for the 
increased insulin demand, glucose tolerance is preserved. Some individuals are 
more susceptible to develop type 2 diabetes mellitus then others. To unravel why 
some obese individuals are more prone to develop diabetes mellitus than others it is 
important to identify the factors that link obesity to diabetes mellitus. These interactions, 
however, are complex and incompletely understood. Multiple potential pathways 
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and most of them function as PRRs as recognize bacterial components. The NLR 
family member pryin domain containing protein (Nlrp)-3 is involved in the activation 
of IL-1β and IL-18 in adipose tissue via the inflammasome. (12-14) 
 The third group of PRR’s are the C-type lectins (CLRs). CLRs contain carbohydrate 
recognition domains. CLRs are important for the recognition of fungi and bacteria. 
Retinoic-acid-inducible gene 1(Rig)-like helicases (RLRs) are the last group of PRRs. 
These cytoplasmatic receptors are important for the recognition of viral nucleic acids.
Although the role of TLR’s in inflammatory signalling during infection and inflammation 
is well established, this is not the case for their role in adipose tissue inflammation. 
As mentioned earlier, TLR-2 and -4 are activated by free fatty acids. TLR-3 deficiency 
has been reported to lead to increased insulin sensitivity and a reduction in hepatic 
steatosis in mice. (15) Furthermore TLR-3 is possibly involved in the pathogenesis of 
type 1 diabetes mellitus. (16, 17)
Macrophages and other immune cells
Once PRR’s are activated a pro-inflammatory response develops. Adipokines and 
chemoattractants like monocyte chemotactic protein-1 (MCP-1) are released, 
resulting in influx of macrophages into the adipose tissue. (18) Eventually this leads to 
clearance of cell debris originating from damaged or dying adipocytes, which 
enables remodelling of the adipose tissue. This pro-inflammatory process induces 
the release of other cytokines like tumour necrosis factor α (TNFα) IL-1 and IL-6. (19)
In obese, insulin resistant patients more dead adipocytes might be present due to 
adipose tissue hypertrophy resulting in local hypoxia. Indeed, the number of 
macrophages in adipose tissue correlates with body mass and adipocyte size. (20) 
The causal link between macrophage infiltration and damaged adipocytes is also 
suggested by the crown-like structures that are characterized by aggregated 
macrophages surrounding dying adipocytes. (19, 20) Macrophages that infiltrate the 
adipose tissue during the development of obesity are suggested to differ from residual 
macrophages, which are present in adipose tissue of lean individuals (figure 1). (21) 
In general, macrophages can be divided in two groups. Residual macrophages in 
lean adipose tissue are considered to have a more anti-inflammatory phenotype, these, 
alternatively-activated macrophages, are coined M2-macrophages. M2-macrophages 
are well equipped to preserve normal function of adipose tissue by promoting tissue 
repair. M2-macrophages are characterised by increased expression of IL-10, arginine-1, 
mannose receptor, c type 2 (Mrc2), IL-1 receptor 2 (decoy receptor) and low expression 
of IL-12. (22)  Infiltrating macrophages in an overfeeding state display a more pro- 
inflammatory phenotype. These, classically activated, macrophages are named 
describe how nutrient excess leads to insulin resistance. Among the factors involved 
are increased fatty acid supply, biochemical adaptations induced by nutrient 
overload, microhypoxia in adipose tissue, endoplasmatic reticulum stress, secretion 
of adipocyte- and macrophage-derived cytokines, chronic tissue inflammation, 
genetic predisposition and fat distribution. In most patients with diabetes mellitus it is 
impossible to point out one specific factor as causative agent. All mentioned pathways 
do influence the development of diabetes mellitus and no common factor or set of 
factors is applicable to all patients. Inflammation might play a role in many of the 
earlier mentioned pathways and high levels of pro-inflammatory markers have been 
shown in insulin resistant individuals. (5) The present thesis focuses on the influence 
of inflammation in the pathogenesis of diabetes mellitus. 
Inflammation and the adipose tissue
Obesity is the consequence of a long-term positive energy balance. Nutrient excess 
and subsequent storage in adipose tissue results in expansion of the adipose tissue 
mass and adipocyte size. This hypertrophy leads to local hypoxia. The combination 
of microhypoxia and nutrient excess leads to induction of the hypoxia-inducible factor 
(HIF)-1 gene program as well as ER stress within the adipocyte. This leads to cell 
death and an inflammatory response characterized by the influx of various pro- 
inflammatory immune cells in obese adipose tissue. (6) Due to dysfunction of 
adipocytes, free fatty acids are released. Free fatty acids have been suggested to be 
ligands of Toll like receptor (TLR)-2 and -4. (7-9) Activation of TLR- receptors induces 
an immune response. (10)
Pattern recognition receptors
While both TLR-2 and -4 seem to be involved in the pro-inflammatory state of the 
adipose tissue it is likely that also other receptors are involved as may other TLRs are 
expressed in adipocytes and pre-adipocytes. (7)
 An inflammatory reaction initiates when a pathogen (exogenous) or danger 
(endogenous) associated molecular pattern (PAMP or DAMP) is recognized. Pathogen 
recognition receptors (PRRs) play a pivotal role in the initiation of an immune 
response.(11) PRRs are present on specialised immune cells like macrophages and 
dendritic cells but also on other non-immune cell types. (11) 
 Four different classes of PRRs are distinguished. The best-known group of PRRs 
are the TLRs a family consisting of 10 members (in humans) that have the capacity 
to recognize different PAMPs or DAMPs. TLR-1, -2 and -6 are activated by bacterial 
lipopeptides, TLR-4 recognizes enterobacterial lipopolysaccharides, the ligand for 
TLR-5 is bacterial flagellin and TLR-3, -7, -8 and -9 detect nucleic acid motifs. Other 
groups of PRRs are nucleotide-binding oligomerization domain (NOD)-like receptors 
NLRs). NLRs are cytoplasmic proteins; more than 20 NLR genes have been detected 
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The IL-1 family comprises at this moment of 11 members. 7 IL-1 family members have 
a pro-inflammatory effect, there are three receptor antagonists and one, IL-37, has an 
anti-inflammatory function. (31) The IL-1 receptor family also includes 11 molecules. 
The receptor molecules form 4 receptor complexes (IL-1Receptor, IL-18 receptor, 
IL-33 receptor and IL-36 receptor), 3 IL-1 receptors are decoy receptors and TIR-8 
does have no known ligand. (31)
Two prominent member of the IL-1 family are IL-1α and IL-1β. IL-1α is constitutively 
present in its active form. When cells become necrotic, IL-1α is directly released in the 
circulation and initiates an immune reaction. Il-1β is mainly, but not exclusively, 
produced by cells of the innate immune system. IL-1β is translated as pro-IL-1β, which 
is not immunologically active. Pro-IL-1β needs to be cleaved into its biologically active 
form. Cleavage is mediated by caspase-1, which is in turn controlled by a pro-
tein-complex called the inflammasome. The inflammasome contains a molecule 
(mostly an NLR) that recognizes DAMPs and PAMPs. For activation of IL-1β typically 
two signals are necessary. A first signal, for example an invading pathogen that 
activates a PRR, which in turn induces IL-1β and NLR transcription. A second signal 
activates the inflammasome. This might be a PAMP, but reportedly also uric acid, 
fatty acids, high glucose levels, islet amyloid polypeptide and adenosine triphosphate, 
can serve as second signal. (30, 32-37) Notably, monocytes do need only one signal 
to release active IL-1β, as these cells do contain constitutively active caspase-1. (38)
 IL-1α and IL-1β both bind to the IL-1R1 and their biological effects are similar.  IL-1 
and IL-1R1 form a complex with the IL-1 receptor accessory protein (IL-1RAcP, also 
IL-1R3), after which an intracellular signalling cascade eventually leads to a potent 
immune reaction. IL-1R2 lacks the intracellular domain of IL-1R1, which is necessary 
for further signalling and functions as a decoy receptor for IL-1. It binds IL-1 with high 
affinity. (29, 30, 39) IL-1R2 does also prevent processing of pro-IL1β into its active 
form by caspase-1. (40) Further IL-1 activity is kept in control by the competitive 
binding of IL-1 receptor antagonist (IL-1RA) to IL-1R1. The affinity of IL-1RA for IL-1R1 is 
higher than the affinity of IL-1 to IL-1R1. Binding of IL-1RA to IL-1R1 does not result in 
recruitment of IL-1RAcP, thus no further intracellular responses occur. (31) IL-1RA also 
binds IL-1R2, although its affinity is quite low in comparison to IL-1. (31) IL-1RA is 
produced in response to the same stimuli as IL-1. 
 
Interleukin-1F6 and Interleukin-1F8
IL-1F6 and IL-1F8 are nowadays designated IL-36α and IL-36β. (41) Both are 
interleukin-1 family members that signal via IL-1 receptor related protein 2 (also IL-1R6) 
and IL-1RAcP. (29) IL-1F5 (also IL-36RA) is a receptor antagonist of IL-1F6 and Il-1F8. 
(42) Il-1F6 and IL-1F8 do induce the production of proinflammatory cytokines and lead 
to Th1 and Th17 cell polarisation. (43-45) It has been shown that IL-1F6 and IL-1F8 are 
 M1-macrophages. M1-macrophages express high levels of IL-12, IL-1 receptor 1 
(IL-1R1) and IL-1 receptor associated protein (IL-1RAcP) and low IL-10. (22) The 
activation state of macrophages in the adipose tissue does likely form a continuum 
between M1 and M2 state. Next to macrophages other immune cells like CD4+, 
CD8+, and regulatory T-cells also contribute to determining the inflammatory trait of 
adipose tissue. (23-26)
Interleukin-1 family 
IL-1 is a key player in the local and systemic response to infections and inflammatory 
challenges. (28, 29) The release of IL-1 has major effects on virtually all organ systems. 
IL-1 release causes fever, triggers an acute phase response, and induces the 
expression of adhesion molecules and chemokines in endothelial cells, leading to 
recruitment of cells of the immune system. (28) The lifespan and effector function of 
neutrophils and macrophages increases. (30) Here the IL-1 family is described with 
special focus on its metabolic effects.
Figure 1  Obesity induced inflammation. 
Adipose tissue of lean individuals is characterized by small adipocytes. The adipose tissue is 
populated by anti-inflammatory macrophages (M2-phenotype), the adipokines that are 
secreted exhibit an anti-inflammatory profile (left picture). When obesity develops, adipose 
tissue and individual adipocytes become hypertrophic. Local hypoxia occurs due to insufficient 
vascularisation. Adipocytes become dysfunctional and necrotic. Cell debris is cleared by 
pro-inflammatory macrophages (M1 phenotype), which sometimes form crown-like structures. 
Adipokines with a more pro-inflammatory profile recruits more pro-inflammatory immune cells 
(right picture). (Figure adapted from Ouchi et al (27))
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levels and HbA1c are inversely related to peripheral insulin sensitivity. (58) In patients 
with type 1 diabetes mellitus, insulin sensitivity is normal when glucose control is 
optimized. (57)
Interleuking-1 and hyperglycemia
As noted above, inflammation may play a causal role in glucose toxicity both at the 
level of insulin sensitivity and beta cell function. It has been shown that high glucose 
levels increase the production of acute phase reactants and pro-inflammatory 
cytokines by adipocytes. (32, 59, 60) Hyperglycemia is shown to induce caspase-1 
mediated interleukin-1β (IL-1β) in beta-cells. (37) Hence, chronic hyperglycemia may 
accelerate the inflammatory response, both at the level of insulin secretion and at the 
level of insulin action.
Anakinra
As IL-1 is important in the development of insulin resistance as well as in decreased 
beta-cell function, it might be beneficial to block IL-1 mediated actions. A number of 
potential interventions is illustrated in figure 2. First, blocking caspase-1 should 
reduce the activation of IL-1, but currently no caspase-1 inhibitor is available for 
clinical use. Another possibility would be to directly block the binding of IL-1 to its 
receptor.  As described earlier, IL-1 actions are constrained by IL-1RA. Anakinra is a 
recombinant human IL-1RA. It has been used as a treatment of rheumatoid arthritis 
and other IL-1 mediated auto-inflammatory diseases. (61) The most frequent side 
effect of anakinra is a transient injection site reaction.  This reaction is the effect of one 
of the solvents of anakinra and is dose dependent. (61) Most patients do not 
experience site reactions after continuing beyond 3 weeks with daily injections. 
Another adverse event is leukocytopenia. Infections appear to be a non-frequently 
occurring adverse event (61, 62). In 2007 Larsen et al. treated patients with type 2 
diabetes mellitus with anakinra 100 mg daily for 13 weeks. Patients treated with 
anakinra had better glycemic control compared to placebo treated patients. HbA1c 
levels and fasting glucose levels decreased. Beta-cell function improved. However, 
no increase in insulin sensitivity was detected by euglycemic-hyperinsulinemic 
clamp, as well as by insulin sensitivity index calculated by the homeostasis model 
assessment. (63) So far, the results of this trial have not been reproduced and clearly 
more detailed information regarding the exact effect of the intervention on insulin 
secretion and sensitivity is needed. 
involved in immunity of the skin and the lung. (46-48) The effects of IL-1F6 and IL-1F8 
on adipocytes and insulin metabolism have not yet been investigated.                                    
Interleukin-1 and insulin sensitivity
IL-1β treatment reduces adipocyte differentiation, as shown in murine 3T3-cells and 
human SGBS cells. Treatment with IL-1β reduces GLUT-4 expression and translocation 
to the cell membrane and reduces expression of the insulin sensitivity markers PPARγ 
and adiponectin, and decreases intracellular lipid accumulation. When IL-1β effects 
are antagonized by the IL-1 receptor antagonist (IL-1RA), differentiation of 3T3 cells 
increases. IL-1β knockout mice are more insulin sensitive than their wild-type 
littermates. (13) Altogether, these results argue that IL-1 contributes to the development 
of insulin resistance of adipocytes.  
 Blockage of caspase-1 using pralnacasan also resulted in improved adipocyte 
differentiation, as shown by higher expression of PPARγ, adiponectin and GLUT4. As 
caspase-1 does also activate IL-18, this effect might theoretically be IL-18 mediated, 
but IL-18 does not affect adipocyte differentiation. (13)
 Interestingly, IL-18 knockout mice are more insulin resistant and obese than their 
wildtype littermates. (49) So, although IL-1β and IL-18 are both substrates of caspase-1, 
their effects on adipocyte differentiation and insulin sensitivity appears to be opposite.
Interleukin-1 and Beta-cell function
Although insulin resistance is preceding decreased beta-cell function in type 2 
diabetes mellitus, type 2 diabetes mellitus does not develop as long as beta-cell 
function compensates for the level of insulin resistance. Beta-cells respond to IL-1 via 
the IL-1R1. High glucose levels result in the activation of caspase-1 and the release of 
IL-1. (32, 50) High IL-1 levels induce beta-cell apoptosis via activation of the 
FAS-receptor (50, 51) and insulin synthesis and release is inhibited by high IL-1 levels. 
(50, 52, 53) Beta cells can be rescued from hyperglycaemia-induced apoptosis by 
addition of IL-1RA. (50) Children with newly diagnosed type 1 diabetes mellitus treated 
with interleukin-1 receptor antagonist for 28 days had lower insulin need as compared 
to historical controls. (54) Thus, IL-1 appears to be involved in the development of 
decreased beta-cell function.
Glucose toxicity
Once diabetes has emerged, chronically elevated glucose levels can further amplify 
beta-cell dysfunction and insulin resistance. This glucose toxicity is best characterized 
at the level of the beta cell and held responsible for the progressive deterioration of 
beta-cell function. (55, 56) Glucose toxicity is also known to affect insulin sensitivity 
as shown in elegant studies in patients with type 1 diabetes that develop insulin 
resistance after a period of 24 hours of hyperglycemia. (57) Both fasting glucose 
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Objectives and outline of the thesis
The overall objective of this thesis is to obtain more insight in the role of inflammation 
in affecting insulin sensitivity and beta cell function.  First we set out to acquire more 
clarity in the instigation of the pro-inflammatory reaction in the adipose tissue. TLR-2 
and TLR-4 have been mentioned to recognize fatty acids, so these, but also other 
PRR’s might be involved in the initiation of the inflammatory response. We first 
measured the expression of a large selection of PRR’s in human subcutaneous 
adipose tissue. The observed expression pattern for TLR-3 was remarkable, as it was 
predominantly present in the adipocyte fraction, as compared to the stromal vascular 
fraction whereas other PRRs showed predominant expression in the stromal vascular 
fraction. In chapter 2 we describe the role of TLR-3 in adipocytes and additionally 
show effects of TLR-3 deficiency on insulin sensitivity and adipose tissue inflammation 
using an in vivo approach.
After investigating the instigation of the pro-inflammatory reaction in the adipose 
tissue did we focus on the effects of novel, possibly important, cytokines on adipose 
tissue inflammation. In chapter 3 have we investigated the effects of two IL-1 family 
members, IL-1F6 and IL-1F8. It has been shown earlier that other members of the IL-1 
family do have important effects on adipose tissue inflammation. Blockade of IL-1, 
using anakinra, resulted in improved fasting glucose levels and is known to result in 
decreased adipocyte differentiation and insulin sensitivity. Further, IL-18 deficiency 
leads to insulin resistance and obesity. IL-1F6 and IL-1F8 activation is known to result 
in the release of pro-inflammatory cytokines. IL-1F6 and IL-1F8 are involved in skin 
and lung immunity. We determined the presence and functional activity of IL-1F6 and 
IL-1F8 in adipocytes. 
As IL-1 is involved in insulin resistance as well as in decreased beta-cell function, 
blockade should result in (partial) reversal of these effects. At the start of the research 
described in this thesis, anakinra was the only, commercially available drug inhibiting 
IL-1 activity.   
To determine the direct effects of IL-1β blockade on insulin resistance, we selected 
patients with the metabolic syndrome, a condition strongly associated with insulin 
resistance. By selecting patients with the metabolic syndrome, but without diabetes, 
we were able to measure the effect of Anakinra both on insulin sensitivity and beta-cell 
function without interfering effects of changes in glycemic levels. The results of this 
trial are reported in chapter 4. 
Figure 2  Treating inflammation by blocking Interleukin-1.
 
1. In case of hypoxia, adipocytes become necrotic and leak cell contents. 2. IL-1α is released in 
the circulation. IL-1α-blockers can block the inflammatory process at this stage. 3. IL-1α binds 
to the IL-1R1 on resident macrophages. This process can be blocked by anakinra of anti-IL-1R1 
antibodies. 4. Inflammatory genes are activated and the IL-1β precursor is produced. 5. The IL1-β 
precursor is cleaved by caspase-1 into active IL-1β. Caspase-1 inhibitors can block this 
cleavage into the active form. 6. Active IL-1β is secreted into the extracellular compartment 
where it can be blocked by anti-IL-1β antibodies or by rilonacept. 7. IL-1β enters the circulation 
as the vascular integrity at the necrotic side diminishes. 8. IL-1β bind to IL-1R1 at the capillaries 
and vascular cell adhesion molecule 1 (VCAM-1) is induced. 9. Circulating monocytes bind to 
VCAM-1 and enter the necrotic area. More IL-1β is produced by the monocytes. 10. Plasma 
proteins enter the ischemic side. 11. Platelet-derived IL-1α binds to IL-1R1 and activates 
intercellular adhesion molecule 1 (ICAM-1). 12. Neutrophils enter the ischemic side. IL-1 
prolongs neutrophil-life. 13. Neutrophil proteases are released. 14. IL-1β precursor released in 
the extracellular space is cleaved by neutrophil proteases, resulting in active IL-1β. Serine 
protease inhibitors can block this cleavage. 15. Increasing numbers of neutrophils enter the 
ischemic side to scavenge cell debris. Neutrophil proteases damage penumbral adipocytes 
resulting in increased loss of function of the adipose tissue. (Figure adapted from Dinarello 
et al. (64))
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In chapter 5 we focused on insulin sensitivity and Anakinra treatment. For this study 
patients with long-standing type 1 diabetes mellitus were included. As these patients 
do not have residual beta-cell function, we were able to specifically monitor effects on 
insulin sensitivity. For this study, overweight patients with suboptimal regulated 
diabetes (HbA1c > 58 mmol/mol) were included. Thus, this study should not only be 
able to detect Anakinra-induced effects on insulin sensitivity by reducing the obesi-
ty-associated inflammation but also by interfering with the chronic hyperglycemia-re-
lated inflammation.
Patients with impaired glucose tolerance have a high risk to develop type 2 diabetes 
mellitus over time. Impaired glucose tolerance is an early manifestation of an 
underlying insulin secretion defect. Based on the in vitro data, we postulated that 
inflammatory changes in general and over activity of the IL-1β pathway in particular 
may contribute to this early insulin secretion dysfunction. This hypothesis was tested 
in the study described in chapter 6 where we determined the effects of IL-1 blockade 
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Introduction
Obesity is a worldwide problem that profoundly affects global health (1). Obesity is 
associated with type 2 diabetes mellitus, cardiovascular disease, hepatic steatosis 
and obesity-related cancers (2). Development of obesity leads to morphological and 
functional changes in adipose tissue. Adipocytes become hypertrophic and immune 
cells, such as macrophages (3, 4), T- and B-cells (5), infiltrate into the adipose tissue 
(6). This inflammatory trait is associated with insulin resistance and subsequently 
type 2 diabetes mellitus. Much remains to be learned about the factors that initiate 
and propagate adipose tissue inflammation. 
 An inflammatory response is initiated when exogenous (pathogen associated 
molecular pattern, PAMP) or endogenous (danger associated molecular pattern, 
DAMP) ligands are recognized by a pattern recognition receptor (PRR). Activation of 
PRRs triggers intracellular signalling cascades, eventually leading to production of 
chemokines and pro-inflammatory cytokines and recruitment and activation of 
immune cells. TNFα, interleukin (IL)-1β, IL-6 and IL-8 are the best-known cytokines 
involved in adipose tissue inflammation and the subsequent development of insulin 
resistance (7-9). Potential DAMPs in adipose tissue, released by dying adipocytes or 
certain lipids, are present in increased concentrations in obesity (10). It is therefore of 
high interest to identify which pattern recognition receptors mediate the link between 
obesity and adipose tissue inflammation. 
 Toll-like receptors (TLRs) are a large class of transmembrane PPRs and well 
known for their role in inflammatory signalling during infection and inflammation (11). 
In humans, ten members of the TLR-family have been described (12). Amongst these, 
TLR-2 and TLR-4 have emerged as important regulators of pro-inflammatory 
signalling in response to saturated fatty acids (13-16), thereby mediating at least part 
of the HFD-induced adipose tissue inflammation (17). In contrast, the role of other 
TLRs in adipose tissue inflammation remains largely unknown. 
 In the present study we screened the expression of all TLR-family members in 
adipose tissue. Remarkably, we identified TLR-3 as being highly expressed in the 
adipocytes, in contrast to other TLRs that were mainly present in the stromal vascular 
fraction of the adipose tissue. Interestingly, TLR-3 can bind mRNA that is released 
from dying cells (18) aside from double-stranded viral mRNA (19), hence may be 
activated by apoptotic adipocytes that are frequently observed within obese adipose 
tissue (20). Therefore, we were prompted to investigate the role of TLR-3 in adipose 
tissue inflammation, using complementary in-vitro and in-vivo experimental models, 
as well as human adipose tissue biopsies.
Abstract
Innate immunity plays a pivotal role in obesity-induced low-grade inflammation 
originating from adipose tissue. Key receptors of the innate immune system including 
Toll-like receptors-2 and -4 (TLRs) are triggered by nutrient excess to promote 
inflammation. The role of other TLRs in this process is largely unknown. In addition to 
double-stranded viral mRNA, TLR-3 can also recognize mRNA from dying 
endogenous cells, a process that is frequently observed within obese adipose tissue. 
Here, we identified profound expression of TLR-3 in adipocytes and investigated its 
role during diet-induced obesity.
Human adipose tissue biopsies (n=80) and an adipocyte cell-line were used to study 
TLR-3 expression and function. TLR-3-/- and WT animals were exposed to a high-fat 
diet (HFD) for 16 weeks to induce obesity.
Expression of TLR-3 was significantly higher in human adipocytes compared to the 
non-adipocyte cells part of the adipose tissue. In vitro, TLR-3 expression was induced 
during differentiation of adipocytes and stimulation of the receptor led to elevated 
expression of pro-inflammatory cytokines. In vivo, TLR-3 deficiency did not 
significantly influence HFD-induced obesity, insulin sensitivity or inflammation. In 
humans, TLR-3 expression in adipose tissue did not correlate with BMI or insulin 
sensitivity (HOMA-IR).
Together, our results demonstrate that TLR-3 is highly expressed in adipocytes and 
functionally active. However, TLR-3 appears to play a redundant role in obesity-in-
duced inflammation and insulin resistance.
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fat cells in five to ten microscopic fields of view were counted and measured. For 
detection of crown-like structures, a CD68 antibody (AbD Serotec, Oxford, UK) was 
used in human samples. In mouse samples, an antibody against F4/80+ (AbD 
Serotec, Oxford, UK) was used. Visualization of the complex was done using 3,3’-di-
aminobenzidene for 5 min. Negative controls were used by omitting the primary 
antibody.
Animals
16 Male TLR-3-/- and 20 male WT mice on a C57Bl/6 background were obtained from 
Jacksons Laboratory and housed in a pathogen-free environment in the animal 
facility of the Radboud University, Nijmegen. The mice were purchased at Jackson 
and housed individually in filter top cages in a separate room, with water and food 
ad libitum. The housing temperature was held at 23°C and a 12:12h light-dark cycle 
was maintained. After a 1-week run-in period on a low-fat diet, the mice were divided 
in a low-fat diet (LFD) and a high-fat diet (HFD) group. The diet contained either 10% 
or 45% energy derived from fat, lard-oil was replaced by palm-oil (D12450B or 12451; 
Research Diet Services, Wijk bij Duurstede, The Netherlands). This diet was continued 
for 16 weeks. Bodyweight of the animals was recorded weekly. After sacrifice, liver 
and epididymal adipose tissue weight were measured. All animal procedures were 
conducted under protocols approved by the animal experimentation committee of 
Radboud University Medical Centre, Nijmegen. 
Insulin tolerance test (ITT) 
An insulin tolerance test was performed after a 4 hours fasting period. 0,75 U of 
insulin per kilogram bodyweight was injected intraperitoneally. Blood glucose levels 
were determined with an Accu-chek glucosemeter (Roche Diagnostics, Almere, The 
Netherlands) at indicated time points after insulin administration.
qPCR 
Total RNA was isolated from adipose tissue using TRIzol (Invitrogen, Carlsbad, CA), 
according to manufacturer’s instructions. RNA was reverse-transcribed (iScript cDNA 
Synthesis Kit, Bio-Rad Laboratories). RT-PCR was performed using specific primers 
(see S2 Table), power SYBR green master mix (Applied Biosystems, Foster City, CA) 
using the Step-one Real-Time PCR system (Applied Biosystems, Foster City, CA). For 
mice samples, we used 36B4 as housekeeping gene. For human samples we used 
B2M as a housekeeping gene.
Insulin 
Insulin levels in humans were measured by the clinical laboratory unit of the Radboud 
University Medical Centre, Nijmegen.
Materials and methods
Human subjects 
Paired subcutaneous (SAT) and visceral adipose tissue (omentum) (VAT) samples 
were obtained according a standardized procedure from 4 patients (two females and 
two males) to investigate expression of TLRs in mature adipocytes (MA) versus the 
stromal vascular fraction (SVF). Tissue biopsies were taken during elective cholecys-
tectomy. Subjects were between 40–60 years old with a body mass index (BMI) of 
25–28 kg/m2. Subjects were normoglycemic. Metabolic, endocrine and chronic and/
or acute inflammatory diseases were excluded. 
 Moreover, adipose tissue samples were obtained from 80 healthy human subjects 
who were recruited through advertisements in local newspapers. We included healthy 
subjects between 40 and 70 years old (see Supp. Table 1). Subcutaneous adipose 
tissue biopsies were obtained under local anesthesia by needle biopsies 6–10 cm 
lateral to the umbilicus. Samples were taken after an overnight fast. TLR-3 expression 
was measured in the adipose tissue biopsies of all subjects. Subsequently, metabolic 
parameters were compared to TLR-3 expression: BMI (<25, n=33; BMI >30, n=18), 
Homeostatic model assessment for insulin resistance (HOMA-IR) levels (<2, n=40; 
>2 n=26, hsCRP plasma levels (<0.5mg/l, n=19; >1.7mg/l, n=19) and number of 
crown-like structures in the adipose tissue (no, n=53; yes, n=19). Furthermore, 
associations were made between adipose tissue TLR-3 expression and the lowest 
and highest quartiles, with respect to mRNA expression levels, of IL-8, monocyte 
chemoattractant protein (MCP)-1, fatty acid binding protein (FABP)4 and adipocyte 
size in the adipose tissue. These are markers for either adipose tissue inflammation 
or adipocyte health. The tissue samples were collected after written informed consent 
from all individual participants, and the protocol was approved by the ethical 
committee of the Radboud University Nijmegen Medical Centre and in accordance 
with the Declaration of Helsinki. 
Stromal vascular and mature adipocyte fractions
The collected SAT and VAT samples were disaggregated using collagenase type 1 
(Gibco, Life Technologies) digestion to isolate adipocytes and the stromal vascular 
fraction (SVF) as described before (21). Purity of the two different fractions was 
confirmed using FABP 4 (adipocytes), and CD45 (hematopoietic cells) (table 1). The 
cellular fractions were subsequently used for RNA isolation, followed by real-time 
PCR analysis, as described below.
Histochemistry
Morphometry of individual fat cells was assessed using digital image analyses as 
described previously (22). In short: for each subject, the adipocyte cell diameter of all 
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post-hoc Bonferroni tests and correlations were evaluated with regression analysis in 
Graphpad Prism 6.0. p-values < 0.05 were considered significant. 
Results
TLR-3 is highly expressed in adipocytes and functionally active
We investigated expression patterns of all TLR-family members in human adipose 
tissue. Adipose tissue biopsies of both subcutaneous and visceral depots were used 
and separated in stromal vascular fraction (SVF) and mature adipocytes (MA). 
Separation of adipocyte and stromal vascular fraction was adequate as determined 
by expression of CD45 and FABP4 in the two fractions (S1 figure a, b). Most TLR-family 
members were more robustly expressed in the SVF fraction compared to the MA 
fraction (e.g. TLR-1, TLR-2), or similarly expressed between the SVF and MA fraction 
(e.g. TLR-6, TLR-7, TLR-8). Remarkably, the expression profile of TLR-3 was different 
from the expression pattern observed for the other TLRs, as it was significantly higher 
expressed in the MA fraction compared to SVF (figure 1a). The only additional receptor 
that was relatively high expressed in adipocytes was TLR-5. However, its expression 
was just 4 times higher in only the visceral adipocytes compared to the stromal 
vascular cells, where TLR-3 had a 6-fold higher expression in adipocytes. This 
difference was apparent for both subcutaneous and visceral adipose tissue. 
Moreover, TLR-3 protein expression in human subcutaneous adipose tissue was 
confirmed by Western Blot (S1 figure c). Additionally, we found that TLR-3 was highly 
induced during differentiation of SGBS adipocytes in vitro (figure 1b), in a similar 
fashion as PPAR-γ, a marker for adipocyte differentiation (figure 1c). 
 Next, we tested whether TLR-3 activation in adipocytes was functionally active. 
Therefore, we treated differentiated adipocytes with poly(I:C), a synthetic TLR-3 
ligand and compared this to E.coli LPS, a TLR-4 ligand. Similar to LPS, poly(I:C) 
significantly increased transcription of pro-inflammatory cytokine IL-8 after 24 hours. 
In addition, poly(I:C) induced expression of MCP-1, a key molecule that mediates 
macrophage infiltration in adipose tissue (24), while IL-1β expression was not 
increased after 24 hours of LPS or poly(I:C) treatment. Furthermore, adipogenic 
genes adiponectin and PPARγ were significantly decreased after Poly(I:C) stimulation 
(figure 2a). To ensure that the effects of poly(I:C) on adipogenic and pro-inflammatory 
cytokine gene expression were specifically mediated by TLR-3, the expression of 
TLR-3 was blocked using small interfering RNA (siRNA). TLR-3 was blocked with a 
knockdown of almost 75% (S2 figure). These data reveal that poly(I:C) increased 
expression of IL-8 and MCP-1 in a TLR-3 dependent manner, since blockage of TLR-3 
with siRNA greatly inhibited the poly(I:C) mediated induction of these genes (figure. 
2b, c). Gene expression levels of IL-1β were unaffected (figure 2d). In contrast, 
Plasma glucose 
Glucose (Liquicolor, Human GmbH, Wiesbaden, Germany) was measured enzymatically 
following manufacturers’ protocols.
Cell lines 
Human Simpson-Golabi-Behmel syndrome (SGBS) preadipocytes were cultured as 
described earlier (23). After full differentiation cells were treated with poly(I:C) 12.5 µg/
ml or lipopolysaccharide 50 ng/ml to stimulate respectively TLR-3 or TLR-4.
Western Blot 
Human subcutaneous adipose tissue samples were analysed for TLR-3 expression. 
Lysates prepared using a lysis buffer [50mM Tris (pH7.4), 150mMNaCl, 2mMED-
TA,1%Nonidet P-40, 50mMNaF,and 0.25% sodium deoxycholate with phosstop 
phosphatase-inhibitor cocktail tablet (Roche) and complete, EDTA-free protease- 
inhibitor cocktail tablet (Roche). The homogenate was centrifuged at 4˚C for 10 min 
at 18.000 rcf and the supernatant was used for Western blot analysis. Equal amounts 
of protein, as determined by a BCA protein assay (Thermo FisherScientific, Rockford, 
IL) were separated using a polyacrylamide SDS page gel. After SDS-PAGE, proteins 
were transferred to a nitrocellulose membrane using a Trans-Blot Turbo Transfer 
System (Biorad) following manufacturer’s instructions. The membrane was blocked 
with 5% (wt/vol) milk powder in Tris-buffered saline (TBS)/Tween 20 for 1 h at room 
temperature followed by incubation overnight at 4 C with a TLR-3 antibody (Abcam, 
ab62566), in 5% (wt/vol) milk powder/TBS/Tween 20. After overnight incubation, the 
blots were incubated with horseradish peroxidase-conjugated secondary antibody 
(goat anti-rabbit, A0545, Sigma Aldrich) at a dilution of 1:5000 in 5% (wt/vol) milk 
powder in TBS/Tween 20 for 1 h at room temperature and subsequently developed 
with ECL plus (Thermo Scientific) according to the manufacturer’s instructions. Bands 
were visualized using a ChemiDoc System (Biorad) and quantified using Image lab 
software (Biorad).
Small interfering RNA
To specifically suppress TLR-3 expression in differentiated adipocytes, cells were 
transfected (X-tremeGENE siRNA Transfection Reagent, Roche) with small interfering 
(si)RNA against TLR-3 (Thermo Scientific). As a nonspecific control, scrambled 
siRNA (Thermo Scientific) was used. After 72 hours of incubation, gene expression 
was determined.
Statistical analysis 
Data are shown as means ± SEM. Differences between groups were analyzed using 
Student’s t test, differences among 4 groups were analyzed with ANOVA followed by 
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TLR-3 deficiency does not affect weight gain or insulin sensitivity 
after HFD-feeding
To test whether TLR-3 is functionally relevant in the process of diet induced obesity 
and insulin resistance, TLR-3-/- mice and WT controls were fed a HFD for 16 weeks. 
TLR-3 deficiency did not influence HFD-induced obesity, compared to WT mice 
(figure 3a). Similarly, liver and epididymal adipose (eWAT) tissue weights were not 
downregulation of adiponectin and PPARγ was not affected by blockage of TLR-3, 
suggesting that other signalling routes besides TLR-3 are likely to play a role in 
down-regulating adipogenesis upon Poly(I:C) stimulation (figure 2e, f). 
Figure 1  TLR-3 is predominantly expressed in adipocytes.
(a) Biopsies from visceral- (VAT) and subcutaneous adipose tissue (SAT) were obtained from 
4 healthy subjects and TLR expression was determined in stromal vascular fraction (SVF) 
and mature adipocytes (MA). mRNA levels of (b) TLR-3 and (c) PPAR-γ were measured during 
differentiation of human SGBS adipocytes. * p < 0.05, ** p < 0.01. Data are shown as 
means ± SEM.
Figure 2  TLR-3 is functionally active in adipocytes.
(a) Differentiated SGBS adipocytes were stimulated with either a TLR-3 (poly:IC 12.5µg/ml) or 
TLR-4 (LPS 50ng/ml) agonist. mRNA levels were measured for IL-8, MCP-1, IL-1β, adiponectin 
and PPAR-γ. (b-f) SGBS adipocytes were treated with SiRNA against TLR-3 or scr SiRNA and 
stimulated with poly:IC. mRNA levels of (b) IL-8, (c) MCP-1, (d) IL-1β, (e) adiponectin, (f) PPAR-γ 
were subsequently measured. * p < 0.05, ** p < 0.01, *** p < 0.001. Data are shown as 
means ± SEM.
a a
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statistically different in TLR-3-/-mice as compared to WT animals (figure 3b, c). The 
latter was confirmed by a similar increase of plasma leptin levels in both genotypes 
due to HFD feeding (figure 3d). Next, we tested whether TLR-3-/- mice were protected 
from HFD-induced insulin resistance. Fasting glucose levels (8 hours) were similar in 
both genotypes, after LFD and HFD-feeding (figure 3e). An insulin tolerance test 
performed 15 weeks after starting the diet intervention showed a tendency towards a 
reduction in insulin sensitivity in HFD-fed TLR-3-/- mice, however this difference did 
not reach statistical (figure 3f, g). 
TLR-3 deficiency does not influence obesity-induced adipose tissue 
inflammation in mice
In a following set of experiments, we assessed whether TLR-3 deficiency affected the 
development of obesity-induced adipose tissue inflammation. Therefore, histological 
sections of eWAT were stained with F4-80, a macrophage marker (figure 4a). No 
differences were found in the number of crown-like structures between TLR-3-/- and 
WT animals (figure 4b). This result was confirmed by similar gene expression levels of 
two macrophage markers, F480 and CD68, as detected by qPCR analysis (figure 4c, 
d). Only monocyte chemoattractant protein (MCP)-1 was slightly higher expressed in 
the absence of TLR-3 (figure 4e). Together, these data suggest that TLR-3 deficiency 
does not affect macrophage infiltration. Additionally, we did not find differences in 
macrophage activation as determined by expression of the pro-inflammatory 
cytokines TNFα and CXCL1 in adipose tissue of TLR-3-/- and WT mice, (figure 4f, g). 
Interestingly, TLR-3 expression itself was not different between HFD- and LFD-treated 
WT mice (figure 4h), while expression of other TLRs was upregulated (TLR-6) or 
tended to increase (TLR-1 and TLR-2) in response to HFD, except for TLR-4 (S3 figure 
a-d). However, expression of these TLRs was not different between TLR-3-/- and WT 
mice fed either a LFD or a HFD, revealing no compensatory up-regulation of other 
TLRs in adipose tissue in the absence of TLR-3. Furthermore, expression of 9 TLRs 
in chow fed mice was measured in stromal vascular cells compared to mature 
adipocytes (S4 figure). Most TLRs, except 2, 4 and 5 were more expressed in stromal 
vascular cells. Thus TLR-3, opposed to human adipose tissue, displayed a lower 
expression level in mouse adipocytes.
TLR-3 in human subcutaneous adipose tissue
Next, we correlated the gene expression levels of TLR-3 in subcutaneous adipose 
tissue samples from 80 healthy donors, with markers of obesity, inflammation and 
insulin sensitivity. TLR-3 expression in subcutaneous adipose tissue was similar 
between lean and obese individuals (figure 5a). Similarly, no difference in TLR-3 
expression was observed between subjects with high insulin sensitivity levels versus 
low insulin sensitivity levels, as determined by the homeostatic model assessment for Fi
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insulin resistance (HOMA-IR) (figure 5b). Subjects with higher systemic inflammation 
(high sensitive C-reactive protein (hs-CRP) levels) or increased adipose tissue 
inflammation (number of crown-like structures) also showed an equal expression of 
TLR-3 (figure 5c, d). In contrast, we found that adipose tissue of subjects with higher 
expression of the pro-inflammatory cytokine IL-8 showed a tendency for lower mRNA 
levels of TLR-3 (figure 5e). A similar tendency was seen for MCP-1 and TLR-3 
expression (figure 5f). On the contrary, FABP4 showed a positive association with 
TLR-3 expression in adipose tissue (figure 5g), although this did not reach statistical 
significance. Finally, despite a high expression of TLR-3 in mature adipocytes, its 
expression did not associate with mean adipocyte cell size in adipose tissue (figure 5h).
Figure 4  TLR-3 deficiency does not ameliorate adipose tissue inflammation.
After 16 weeks of low fat diet (LFD) or high fat diet (HFD) intervention, adipose tissue of wild-type 
(WT) and TLR-3-/- mice was investigated for inflammatory parameters. (a) Adipose tissue of 
mice stained for F4/80, magnification 20x, (b) number of crown-like structures in adipose tissue. 
Inflammatory markers were measured (c) F480, (d) CD68, (e) MCP-1, (f) TNFα, (g) CXCL1. 
(h) mRNA levels of TLR-3 in WT mice fed a LFD or HFD for 16 weeks. * p < 0.05, ** p < 0.01. 
Number of mice per group: WT-LFD n=10; WT-HFD n=10; TLR-3-/-LFD n=7; TLR-3-/-HFD 
n=9. Data are shown as means ± SEM. Figure 4  Continued.
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Discussion
Innate pattern recognition receptors (PRRs) are increasingly recognized as direct or 
indirect sensors of excessive nutrients instigating a chronic inflammatory response in 
adipose tissue during obesity, with possibly detrimental effects on insulin sensitivity 
levels (10). During this metaflammation (7), the function of TLR-3, stimulated by dou-
ble-stranded mRNA and yielding production of type-1 Interferons (19), remains 
largely unknown. In the current study we examined whether TLR-3-signalling is 
involved in the development of adipose tissue inflammation and insulin resistance 
during the development of obesity. To study a potential role of TLR-3 triggered by its 
remarkable high expression in adipocytes, as compared to other members of the 
TLR family. We show that TLR-3 is active in adipocytes upon stimulation with specific 
ligands. However, TLR-3-/- mice showed no significant amelioration in adipose tissue 
inflammation and insulin sensitivity after HFD-feeding. Additionally, data obtained 
from 80 human adipose tissue biopsies showed a limited association of TLR-3 gene 
expression levels with various metabolic abnormalities including insulin resistance 
and adipose tissue inflammation. Together, these data suggest that although TLR-3 
is predominantly expressed in adipocytes and functionally active, it has a limited role 
in mediating 16 weeks HFD-induced adipose tissue inflammation and systemic 
insulin sensitivity in mice, nor a profound association with metabolic abnormalities in 
humans.
 Interestingly, TLR-3 is preferentially expressed on adipocytes as compared to 
stromal vascular cells suggestive of a functional role of the receptor specifically in 
these cells. Indeed, our data demonstrate that stimulation of TLR-3 increases pro-in-
flammatory cytokine expression, an effect that was abolished by silencing of TLR-3 in 
adipocytes using siRNA. Thereby, we confirm that adipocytes can produce cytokines 
after specific TLR-3 stimulation (25). Moreover, TLR-3 was up-regulated during differ-
entiation of adipocytes. The high expression levels led us to believe that TLR-3 may 
exert a more dominant role in adipose tissue as compared to other TLR-family 
members.   
 However, despite its prominent expression and function in adipocytes, in vivo 
studies using TLR-3-/- mice revealed no amelioration in adipose tissue inflammation 
or insulin sensitivity levels as compared to WT mice after 16 weeks of HFD-feeding. 
The difference in expression pattern of TLR-3 in adipocytes vs stromal vascular 
fraction between mouse and human adipose tissue may explain at least some of our 
apparent conflicting observations between in vitro and in vivo results. In addition, we 
observed a different effect of TLR-3 deficiency on MCP-1 expression between the in 
vitro and in vivo experiments. These divergent responses may be explained by 
differences in model-complexity or a different response to TLR-3 signalling in human 
versus murine cells (26). 
Figure 5  TLR-3 in human adipose tissue.
Subcutaneous adipose tissue samples of 80 healthy individuals were obtained. TLR-3 mRNA 
levels were associated with (a) BMI, (b) HOMA-IR, (c) plasma CRP-levels, (d) number of 
crown-like structures in adipose tissue. Association of MAP3K8 mRNA expression in human 
subcutaneous adipose tissue with mRNA expression of (e) IL-8, (f) MCP-1, (g) FABP4 and 
(h) adipocytes cell size. * p < 0.05. Data are shown as means ± SEM. HOMA-IR = Homeostatic 
Model Assessment for insulin resistance.
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 As it is hypothesised that viruses play a role in the pathogenesis of type 1 
diabetes, it might be interesting to investigate the role of TLR-3 in the pancreas. 
Several studies have showed a link between TLR-3 induced islet inflammation and 
type 1 diabetes (22-24). Because 16 weeks is not long enough to induce islet 
inflammation in mice in contrary to adipose tissue inflammation, our study was able 
to investigate the effects of TLR-3 without confounding effects of the pancreas.
 In line with the results from the animal study that did not reveal a vital role for 
TLR-3 in mediating obesity-induced inflammation and the development of insulin 
resistance, the function of the receptor in human adipose tissue appears to be 
relatively small. However, as shown in literature (27), TLR-3 may exacerbate metabolic 
abnormalities in the liver after 33 weeks of HFD in mice as opposed to adipose tissue. 
Moreover, we observed no clear associations in humans, suggesting that TLR-3 has 
a limited role in mediating adipose tissue inflammation and the development of insulin 
resistance. However, these results do not completely rule out any function of 
TLR-3-signalling in adipose tissue during the presence of obesity. Noticeably, our 
results were obtained using subcutaneous adipose tissue biopsies and not the 
metabolically more active visceral depot. In addition to gene expression levels, future 
studies should also determine the activity of TLR-3-dependent signalling routes 
within adipose tissue by measuring TLR-3 protein levels and possible intracellular 
downstream targets. 
 Altogether, these data show that TLR-3 is highly expressed in adipocytes as 
compared to the stromal vascular cells and is functionally active. Nevertheless, in 
mice after 16 weeks of HFD and in humans, the data does not support a fundamental 
role for TLR-3 in the development of obesity-induced adipose tissue inflammation 
and insulin resistance. 
Statement on the Welfare of Animals
Ethical Approval: All applicable international, national and/or institutional guidelines 
for the care and use of animals were followed. All procedures performed in studies 
involving animals were in accordance with the ethical standards of the institution or 
practice at which the studies were conducted.
 Our in vivo results are partly in contrast to a recent report demonstrating that the 
absence of TLR-3 or its blockage using a specific antibody led to improvements in 
glucose tolerance (27). However, in line with our results, a glucose tolerance test 
performed by Wu et al after 14 weeks of HFD revealed no differences between WT 
and TLR-3-/- animals compared to WT mice. Only after 26 weeks of HFD-feeding, the 
absence of TLR-3 led to an improvement in glucose tolerance. Moreover, the absence 
of TLR-3 protected against the development of hepatic steatosis after 33 weeks of 
HFD and reduced expression levels of TNFα in liver. Our research advances these 
studies by specifically focussing on establishing a role for TLR-3 in adipose tissue. 
Possibly, TLR-3 exerts differential effects in the liver versus adipose tissue during the 
development of HFD-induced obesity. More likely, the opposite outcomes are 
explained by differences in study design. The diet intervention in our study was done 
using a low fat diet and high fat diet containing 45% of energy derived from fat. Wu et al 
used a high fat diet with 60% of energy from fat with chow diet as control feeding. 
Additionally, the intervention period lastly for a total period of 33 weeks whereas our 
study design included only 16 weeks of HFD-feeding. 
 Hence, these outcomes may suggest that the absence of TLR-3 ameliorates 
metabolic abnormalities induced by high fat diet feeding only after a prolonged time 
of diet intervention. One might speculate that the ligand responsible for activation of 
TLR-3 only becomes available after long term and very high fat diet feeding. 
 Although many TLRs have both endogenous and exogenous stimuli, the 
endogenous activator of TLR-3 remains to be established. Based on current knowledge, 
TLR-3 primary function is to recognize double stranded RNA and contributes to the 
host defence against viruses. What type of endogenous activator in adipose tissue 
might propel TLR-3 activation is currently unknown, however it has been shown that 
TLR-3 also recognizes single-stranded mRNA (18). In obesity, dying adipocytes may 
therefore release mRNA, which is then recognized by TLR-3. However, in spite of its 
high expression levels in human adipocytes that may suggest otherwise, our results 
do not provide evidence for a vital, important role of TLR-3 in adipose tissue during 
diet-induced obesity. The high expression of TLR3 in the adipocyte fraction of human 
adipose tissue, however, suggest a possible other role in human adipocyte function. 
Recently, it was discovered that activation of TLR-3 reduces adipocyte differentiation 
(28) and that this resulted in inhibited insulin and glucose signalling (29). As TLR-3 
may be involved in the recognition of dying adipocytes, the necrotic cells may thereby 
directly influence surrounding pre-adipocytes and inhibit their differentiation and 
suppress glucose and insulin signalling. Moreover, although especially TLR-2 and 
TLR-4 have been implicated in mediating the pro-inflammatory actions of free fatty 
acids, we cannot rule out that TLR-3 mediates some of these free fatty acids related 
effects.
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Supporting information
Figure S1  Human adipose tissue.
Biopsies from visceral- (VAT) and subcutaneous adipose tissue (SAT) were obtained from 
4 healthy subjects and TLR expression was determined in stromal vascular fraction (SVF) 
and mature adipocytes (MA). mRNA levels of (a) FABP4 (b) CD45. (c) Western blot was used 
to confirm TLR-3 protein expression in human subcutaneous adipose tissue. * p < 0.05, 
** p < 0.01, *** p < 0.001. Data are shown as means ± SEM.
Figure S2  Knockdown of TLR-3 in SGBS cells.
SGBS cells where transfected with small interference RNA against TLR-3 to reduce expression 
of TLR-3. Gene expression was determined after 72 hours. *** p < 0.001. Data are shown as 
means ± SEM.
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Figure S3  TLR expression in epididymal adipose tissue after HFD.
After 16 weeks of low fat diet (LFD) or high fat diet (HFD) intervention, adipose tissue of wild-type 
(WT) and TLR-3-/- mice was investigated for TLR expression. mRNA levels of (a) TLR-1, (b) TLR-2, 
(c) TLR-4 and (d) TLR-6 were measured. * p < 0.05, ** p < 0.01. Number of mice per group: 
WT-LFD n=10; WT-HFD n=10; TLR-3-/-LFD n=7; TLR-3-/-HFD n=9. Data are shown as 
means ± SEM.
a
c
b
d
Figure S4  TLR expression in epididymal adipose tissue in chow-fed mice.
mRNA levels of 9 different TLRs were measured adipocytes versus stromal vascular cells in 
chow fed mice. Number of mice per group: adipocytes n = 9, stromal vascular cells n = 9. Data 
are shown as means ± SEM. * p < 0.05, ** p < 0.01, *** p < 0.001. Data are shown as means 
± SEM.
Supplementary Table 1  Subject characteristics.
This table lists information on the subjects of which adipose tissue biopsies were investigated.
Subcutaneous adipose tissue biopsies
N 80
% male 48%
Age (years) ± SD 54,7 ± 8,4
BMI (kg/m2) ± SD 27,7 ± 4,8
Fasting glucose (mmol) 5,1 ± 0,6
HOMA-IR ± SD 2,3 ± 2,1
hs- CRP (mg/L) ± SD 1,6 ± 1,7
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Supplementary Table 2  Primer Sequences.
This table lists all sequences of the primers that where used in this investigation.
Primer name Sequence Forward (5’> 3’) Sequence Reverse (5’> 3’) 
m36B4 AGCGCGTCCTGGCATTGTGTGG GGGCAGCAGTGGTGGCAGCAGC 
mCD68 CCAATTCAGGGTGGAAGAAA CTCGGGCTCTGATGTAGGTC 
mF4/80 CTTGGCTATGGGCTTCCAGTC GCAAGGAGGACAGAGTTTATCGTG 
mMCP-1 CCCAATGAGTAGGCTGGAGA TCTGGACCCATTCCTTCTTG 
mTNF-α CAACCTCCTCTCTGCCGTCAA TGACTCCAAAGTAGACCTGCCC 
mCXCL-1 TGGCTGGGATTCACCTCAA GAGTGTGGCTATGACTTCGGTTT 
mTLR-3 GGGGTCCAACTGGAGAACCT CCGGGGAGAACTCTTTAAGTGG
mTLR-1 TCAAGCATTTGGACCTCTCCT TTGTACCCGAGAACCGCTCA
mTLR-2 AACCTCAGACAAAGCGTCAAATC ACCAAGATCCAGAAGAGCCAAA
mTLR-4 TTCCTTCTTCAACCAAGAACATAGATC TTGTTTCAATTTCACACCTGGATAA
mTLR-5 GCAGGATCATGGCATGTCAAC ATCTGGGTGAGGTTACAGCCT
mTLR-6 AGGAACCTTACTCATGTCCCC TGTTGTGGGAGAGTCTCAGAA
mTLR-7 TCTTACCCTTACCATCAACCACA CCCCAGTAGAACAGGTACACA
mTLR-8 GAAAACATGCCCCCTCAGTCA CGTCACAAGGATAGCTTCTGGAA
mTLR-9 TGAAGTCTGTACCCCGTTTCT GTGGACGAAGTCAGAGTTGT
   
hTLR-1 CAGGCCCTCTTCCTCGTTAGA TTCCTAAAGGTAGAAGCTGTTCTTCA
hTLR-2 GAATCCTCCAATCAGGCTTCTCT GCCCTGAGGGAATGGAGTTTA
hTLR-3 TTTGCGAAGAGGAATGTTTAAATCT CACCTATCCGTTCTTTCTGAACTG
hTLR-4 GGCATGCCTGTGCTGAGTT CTGCTACAACAGATACTACAAGCACACT
hTLR-5 TGCTAGGACAACGAGGATCATG GTTGCAGAAACGATAAAAGGCTATT
hTLR-6 CACAGAACAGCATTCCCAACA AAAGAGCCCACGTTTGCTTTT
hTLR-7 GATTGAAACCTGACCAATTTGCT AAATACGACATCGCCAATCTAAGG
hTLR-8 GGTCCTCTGCTCAGGGTGTCT TGAATCCAGAAAACAACCACATG
hTLR-9 GGCCCCCGGCTTCTT CAGGAGTGGTCCACTGTCTTGA
hTLR-10 GCATTCCCACCAGGTATCATAAAC AAAGCCCACATTTACGCCTATC
hPPARg ATTGACCCAGAAAGCGATTCC TCTTCCATTACGGAGAGATCCAC
hIL-8 ACTGAGAGTGATTGAGAGTGGAC AACCCTCTGCACCCAGTTTTC
hMCP-1 CCAGTCACCTGCTGTTATAAC TGGAATCCTGAACCCACTTCT
hIL-1β CAGCTACGAATCTCCGACCAC GGCAGGGAACCAGCATCTTC
hAdiponectin ATCGGTGAAACCGGAGTACC GCATGTTGGGGATAGTAACGTAA 
FABP-4 AGCACCATAACCTTAGATGGGG CGTGGAAGTGACGCCTTTCA
The effect of the interleukin-1 cytokine 
family members IL-1F6 and IL-1F8  
on adipocyte differentiation
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Introduction
There is strong evidence that inflammation represents an important link between 
obesity and the development of insulin resistance. (1) Obesity not only results in 
macrophage infiltration promoting inflammation, it also shifts the activation state of 
adipose tissue macrophages (ATM’s) to a pro-inflammatory M1 phenotype. (2)
 The Interleukin (IL)-1 family, with its most prominent members IL-1 and IL-18, is a 
central player of obesity-induced inflammation and insulin resistance. (3) 
 IL-1F6 and IL-1F8 are new members of the IL-1 family of cytokines, and display 
pro-inflammatory effects reminiscent of IL-1 activity. (4) We hypothesized that IL-1F6 
and IL-1F8 are expressed in adipose tissue and influence adipocyte differentiation.
Materials and methods
Human adipose tissue
Human subcutaneous abdominal adipose tissue, obtained from patients undergoing 
reconstructive surgery, was cultured in DMEM (GIBCO) and treated with lipopolysac-
charide (LPS) at 10 ng/ml (Escherichia coli serotype 055:B5) (Sigma). Additionally, 
adipose tissue was separated in adipocytes and stromal vascular cells using 
collagenase (Sigma, St Louis, MO) digestion.
Animal study
Male C57/Bl6 mice were injected intraperitoneally with LPS (1 mg/kg bodyweight). 4 
Hours after injection, animals were sacrificed and epididymal white adipose tissue 
was isolated.
Cell culture
Human SGBS preadipocytes and primary human adipocytes were cultured as 
described earlier. (5) After full differentiation, LPS (10 ng/ml) was added for 24 hours.
During differentiation, primary human adipocytes were treated with IL-1F6 (100 ng/ml), 
IL-1F8(100 ng/ml) or IL-1β (10 ng/ml). The concentrations chosen for IL-1F6 and IL-18 
were based on study of Towne et al. (6), who demonstrated that 100 ng/ml was the 
lowest concentration that significantly activated the NF-κB pathway.
Macrophages
Peripheral blood mononuclear cells (PBMCs) were isolated, differentiated towards 
M1 or M2 macrophages and cultured as described earlier. (7) Macrophages were 
stimulated for 24 hours with LPS (10 ng/ml). 
Abstract
Obesity is characterized by chronic low-grade inflammation originating from expanding 
adipose tissue. In the present study we examined the adipogenic expression levels 
of  IL-1F6 and IL-1F8, both members of the IL-1 family of cytokines, and their effects on 
adipose tissue gene expression. Whereas IL-1F6 is primarily present in adipose 
 tissue-resident macrophages and induced by inflammation, IL-1F8 is absent. IL-1F6, 
but not IL-1F8, reduces adipocyte differentiation, as shown by a significant decrease 
in  PPARγ gene expression. Finally, both IL-1F6 and IL-1F8 are able to induce 
inflammatory gene expression in mature adipocytes.  In conclusion, we demonstrate 
for the first time that IL-1F6 is present in adipose tissue and that IL-1F6 and IL-1F8 are 
involved in the regulation of adipose tissue gene expression. Importantly, IL-1F6 
inhibits PPARγ expression  which may lead to reduced adipocyte differentiation 
suggesting metabolic effects of this cytokine.
Keywords
Interleukin-1F6, Interleukin-1F8, adipose tissue, inflammation
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RAW 264.7 mouse monocytic cells were cultured in DMEM containing 10% FCS and 
treated with LPS during 24 hours.
RT-PCR
Total RNA was reverse transcribed followed by quantitative PCR analysis using the 
Biorad 7300 Real-Time PCR system (Applied Biosystems) with β2M (human) or 36B4 
(mouse) as housekeeping genes.
Statistical analysis
Differences were analyzed by the Student’s t test. P ≤ 0.05 was considered to denote 
significance.
 All applicable institutional and governmental regulations concerning the ethical 
use of human volunteers and animal models were followed during this research.
Results
Expression of IL-1F6 and IL-1F8 in adipose tissue and in cell cultures
IL-1F6 was expressed in adipose tissue, while IL-1F8 was not detected. Although 
IL-1F6 was primarily expressed in the stromal vascular fraction, expression was also 
detectable in adipocytes. (figure 1).
 We used LPS as a model of inflammation to study the effects on IL-1F6 and IL-1F8 
gene expression. (8) qPCR analysis revealed that IL-1F6 and IL-1β, but not IL-1F8 were 
significantly up regulated in white adipose tissue of LPS-treated animals (figure 1).
 Next, we tested the responses of adipocytes and macrophages to LPS treatment 
in vitro. IL-1F6 expression was significantly higher in human SGBS adipocytes (figure 1), 
as well as in RAW 264.7 cells (table 1) after LPS treatment.
 Inasmuch adipose tissue contains differentially polarized macrophages, we 
compared IL-1F6 and IL-1F8 expression in M1 and M2 macrophages. IL-1F6 was 
predominantly produced by M2 macrophages (figure 1). LPS induced IL-1F6 
expression significantly in M2 macrophages (figure 1). IL-1F8 was produced mainly 
by M1 macrophages (figure 1) and LPS did not significantly induce IL-1F8 expression 
(figure 1).
IL-1β-like effects of IL-1F6 on adipocyte differentiation 
Cytokines of the IL-1 family can affect differentiation and function of adipocytes. (9) 
We determined the effect of IL-1F6 and IL-1F8 on expression of four adipogenic genes.
Expression of PPARgamma was significantly down regulated after treatment with 
IL-1F6 (table 1). FABP4, Adiponectin and glucose transporter 4 (GLUT4) expression 
showed a non-significant trend to down regulation (table 1). IL-1F8 had no significant 
Figure 1  IL-1F6 and IL-1F8 expression.
Expression of IL-1F6 and IL-1F8 in SVF and adipocyte fraction (AF) of human adipose tissue (a). 
Adequacy of fraction separation is shown by EMR1 (macrophage marker) and leptin (adipocyte 
marker) expression (b). Expression of IL-1F6, IL-1F8 and IL-1β with and without LPS stimulation 
in mice adipose tissue (c), SGBS adipocytes (d), RAW 264.7 macrophages (e), M1 macrophages 
(f), M2 macrophages (g). Data are presented as mean ± standard error of the mean for 3 or 
more experiments combined. *p<0.05, **p<0.01, ***p<0.005.
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list of cytokines that are involved in the link between obesity and adipose tissue 
inflammation and probably insulin resistance. These findings may also be relevant to 
PPARγ-agonists, which are used in the treatment of diabetes mellitus. It is tempting 
to hypothesize that  blockade of IL-1F6 and IL-1F8 may have therapeutic potential in 
obesity or insulin resistance by relieving a blockade of PPARgamma expression. It 
has been shown earlier in vivo that IL-1F5 antagonizes the effects of IL-1F6, (11) and 
the pathophysiologic consequences of this finding for the adipose tissue remain te 
be investigated.  
 Further research is necessary to determine whether the effect of IL-1F6 on 
adipocyte differentiation is a direct or indirect effect.
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effect on expression of these adipogenic genes (table 1). Finally, IL-1F6 and IL-1F8 
were both able to significantly induce the expression of IL-6 and IL-8 in human 
adipocytes (table 1).
Discussion
In this study, we report for the first time that the novel member of the interleukin-1 
cytokine family IL-1F6, but not IL-1F8, is present in adipose tissue and may be involved 
in the inflammatory link between obesity and insulin resistance. Adipose tissue-resi-
dent macrophages appear to be the primary source of IL-1F6.
 We speculated that IL-1F6 and IL-1F8 may induce an IL-1β like response in adipose 
tissue, (9) since IL-1F6 and IL-1F8 activate equal signaling pathways as IL-1β, using partly 
similar cellular receptors. (6) Our results demonstrate that IL-1F6 can inhibit adipocyte 
 differentiation, although less effective than IL-1β. Perhaps higher concentrations of 
IL-1F6 would lead to more pronounced results since the used dose of IL-1F6 is the 
lowest dose that induces a significant increase of NF-κB and IL-6 and IL-8 gene 
expression levels were much higher after stimulation with IL-1β 10 ng/ml compared to 
IL-1F6 100 ng/ml. (6) Nevertheless, both IL-1-F6 and IL-1F8 are able to induce 
responses in adipocytes albeit the effectiveness is lower as compared to IL-1β.
 We were surprised by the finding that IL-1F6, which seems to have  pro-inflammatory 
effects on adipocyte differentiation, was primarily produced by M2 macrophages, but 
new insights show that ATMs with an M2 phenotype can also produce high amounts 
of pro-inflammatory cytokines, in fact even more than M1 macrophages. (10) 
 The finding that IL-1F6 is present in adipose tissue and inhibits PPARgamma 
expression and probably adipocyte differentiation adds an additional mediator to the 
Table 1   Expression of FABP4, PPARgamma, Adiponectin, GLUT4, IL-6 and IL-8 in 
primary human adipocytes treated with or without IL-1F6, IL-1F8 or IL-1β.
Control IL-1F6
100ng/ml
IL-1F8
100 ng/ml
IL-1β
10 ng/ml
FABP4 1.00 0.82±0.06 0.88±0.14 0.00±0.00***
PPARgamma 1.00 0.62±0.08* 1.17±0.22 0.02±0.01***
Adiponectin 1.00 0.71±0.07 0.89±0.27 0.01±0.00***
GLUT4
IL-6
1.00
1.00
0.6±0.12
1.75±0.11***
0.75±0.41
1.05±0.05
0.27±0.20
16.94±0.99***
IL-8 1.00 9.00±2.70* 3.69±0.82* 1065±40***
*p<0.05, **p<0.01, ***p<0.005.
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Introduction
The global prevalence of obesity is rapidly rising and paralleled by an increasing 
incidence of insulin resistance and type 2 diabetes mellitus. Although the pathophys-
iological basis underlying obesity-associated insulin resistance has not been fully 
unravelled, many reports suggest that chronic low grade inflammation originating 
from adipose tissue represents an important link. (1) 
Storage of excess energy results in expansion of adipose tissue mass and an 
increase in adipocyte size. Concurrent with this expansion, oxygen delivery to the 
adipocyte is decreased and may eventually lead to microhypoxia and adipocyte 
death. Together with the enhanced pro-inflammatory profile of enlarged adipocytes, 
(2) this results in the recruitment of macrophages that further amplify the inflammatory 
status of the adipose tissue. (3) Pro-inflammatory cytokines as tumor necrosis factor 
α and IL-6 that are released in increased amounts by adipocytes and activated 
macrophages of obese individuals can induce insulin resistance. (4, 5)
In addition to its role in immunity, the pro-inflammatory cytokine Interleukin (IL)-1 
(both IL-1a and IL-1²) is also involved in the development of diabetes mellitus. By 
inducing beta-cell destruction, IL-1 contributes to the pathogenesis of type 1 diabetes 
mellitus. (6) Furthermore, a positive association between IL-1 levels and the presence 
of obesity has been found. (7) IL-1β induces insulin resistance in cultured human 
adipocytes (8) and primary rat hepatocytes (9) and IL-1β knockout mice are more 
insulin sensitive as their wildtype littermates. (10, 11) Based on these observations, 
one might expect that blockade of IL-1β would improve insulin resistance in humans.
IL-1β exerts its effects by binding to the type 1 IL-1receptor (IL-1R). (12) This results in 
recruitment of IL-1 receptor accessory protein (IL-1RAcP), necessary for signal 
transduction. (13) Activation of IL-1R leads to fever, synthesis of acute phase proteins, 
leukocytosis, thrombocytosis and anemia. (14) IL-1Receptor antagonist (IL-1RA) 
inhibits IL-1β action by competing with IL-1β for binding to the IL-1R. Binding of IL-1RA 
to the IL-1R does not result in recruitment of IL-1RAcP and thereby blocks intracellular 
signalling. (13)
 Blocking the IL-1 effects in patients with type 2 diabetes mellitus by anakinra, a 
recombinant human IL-1RA, has been shown to improve glycemic control. Whether 
IL-1 blockade has a beneficial effect on insulin sensitivity in non-diabetic subjects 
characterized by insulin resistance remains to be determined.
Abstract
Context: Obesity induces chronic low-grade inflammation in adipose tissue that may 
promote the development of insulin resistance. IL-1 is one of the key inflammatory 
factors. 
Objective: To demonstrate an improvement of total body insulin sensitivity by blocking 
IL-1. Secondary objectives were adipose tissue-specific changes and effects on 
inflammation.
Design: randomized double blind cross-over study.
Setting: ambulatory care 
Participants: Non-diabetic, obese subjects with the metabolic syndrome.
Intervention: 150 mg of anakinra subcutaneously once daily or matching placebo 
for 4 weeks.
Main outcome measure: insulin sensitivity as measured by euglycemic  hyper - 
insulinemic clamp. 
Results: A total of 13 out of 19 subjects completed the study. Although anakinra 
treatment resulted in a significantly lower level of inflammation illustrated by a reduction 
in circulating CRP concentrations and leukocyte numbers, insulin sensitivity was 
not significantly different after anakinra treatment (2.8 x 10-2 ± 0.5 x 10-2) compared 
to placebo treatment (2.4 x 10-2 ± 0.3 x 10-2 µmol kg-1 min-1  pmol-1, P = 0.15).
Adipose tissue examination, performed to analyse local effects of IL-1Ra, showed an 
increased influx of macrophages after treatment with anakinra most likely due to an 
injection site reaction caused by the vehicle (0.28 ± 0.05 vs. 0.11 ± 0.01 macrophages 
per adipocyte, P = 0.005). The differences in individual subject insulin sensitivity after 
anakinra as compared to placebo between subjects was negatively correlated with 
macrophage infiltration into the adipose tissue (r2 = 0.46, P = 0.01).
The disposition index increased significantly after anakinra treatment (P = 0.04) 
reflecting an improvement in Beta-cell function. However, other measurements of 
Beta-cell function did not show any differences. 
Conclusions: Our results suggest that anakinra does not improve insulin sensitivity 
in obese, insulin-resistant, non-diabetic subjects.
Clinical trial registration number
NCT00928876, Clinicaltrials.gov.
Keywords 
inflammation, insulin sensitivity, interleukin-1 receptor antagonist
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Study procedures
At the end of both treatment periods we performed a euglycemic hyperinsulinemic 
clamp (insulin infusion rate 360 pmol/m2/min, (18) and on a separate day a 75 gram 
oral glucose tolerance test, with measurement of glucose, insulin and pro-insulin at 
baseline and at 30, 60, 90 and 120 minutes.
 A subcutaneous fat biopsy was obtained and analyzed for adipose tissue 
morphology and macrophage influx. All study procedures were performed after an 
overnight fast.
Subcutaneous adipose tissue biopsy
A subcutaneous adipose tissue biopsy was taken from the abdominal region just 
before the clamp, about 30 minutes after a subcutaneous injection with placebo or 
anakinra to analyze local effects of the active substance (recombinant IL-1Ra) of 
In the present study, we investigated whether blocking IL-1 by recombinant IL-1Ra in 
humans for four weeks can improve insulin sensitivity in non-diabetic, obese, insulin 
resistant subjects with the metabolic syndrome.
Materials and methods
Study design
Overweight subjects with the metabolic syndrome, yet no type 2 diabetes mellitus, 
were included in this randomized, double blind, placebo-controlled, two period, 
crossover study. Subjects were recruited by means of advertisements in a local 
newspaper and from the outpatient clinic of the Radboud University Nijmegen 
Medical Centre. We compared recombinant human IL-1Ra (150 mg of anakinra) with 
matching placebo. Study medication was self-administrated subcutaneously once 
daily for four weeks. Between both treatment periods there was a four week wash-out. 
Because prior studies suggest that the conventional dose of 100 mg anakinra once 
daily is not sufficient in patients with high body weight, (15) the dose was increased 
to 150 mg daily. This dose has been applied in patients with rheumatoid arthritis. (16)
Anakinra was purchased from the regular manufacturer (Biovitrum), the study was 
performed completely independent from any company. The Pharmacy department 
of Radboud University Nijmegen Medical Centre prepared all study medication and 
was responsible for the blinding and randomization procedure. Subjects were 
randomized in blocks of four, in a 1:1 allocation ratio.
Participants
The study was approved by the institutional ethics review board and assessed by 
an independent monitor. Written informed consent was obtained from all subjects 
before randomization.
 Inclusion criteria were: age 18 years or older, body mass index > 30 kg/m2 and 
3 or more characteristics of the metabolic syndrome according to the definition of the 
third report of the National Cholesterol Education Program’s Adult Treatment Panel 
(NCEP-ATP-III). (17)  Exclusion criteria were the known presence of diabetes mellitus, 
a fasting plasma glucose 7.0 mmol/L or higher, HbA1c 6.2 % or higher, immunodefi-
ciency or immunosuppressive treatment, current use of anti-inflammatory medication 
(100 mg or less of aspirin per day was allowed), signs of current infection or treatment 
with antibiotics, a history of recurrent infections or tuberculosis, pregnancy or breast 
feeding, a serum alanine aminotransferase or aspartate aminotransferase level of 
more than three times the upper limit of the normal range, a serum creatinine level 
higher than 130 µmol/l, neutropenia (a leukocyte count of less than 2x109/l), or the 
presence of any other medical condition that might interfere with the current study 
protocol and inability to give informed consent
Figure 1  Design, enrollment, withdrawal and completion of the study.
Assessed for eligibility (n=32) 
Excluded (n=13)
- Not meeting inclusion criteria (n=12)
- Refused to participate (n=1) 
Analysed (n=13)
results of paired data were compared
intra-individually 
Discontinued intervention (n=6) 
- Injection side reaction (n=2)
- Physical load of tests (n=2)
- H1N1 infect (n=1)
- Wound infect (n=1)
Received intervention (n=19) 
Randomized (n=19)
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 Measurements of other parameters were performed in the clinical laboratory unit 
of the Radboud University Nijmegen Medical Centre.
Statistical analysis
We considered a 20% improvement of the primary endpoint, insulin sensitivity, as 
determined by euglycemic hyperinsulinemic clamp, as clinically relevant. Assuming 
a test-to-test correlation coefficient of 0.5 (paired tests) and a mean glucose infusion 
rate of 30 ± 7 µmol/kg/min, would require a total of 11 subjects to detect a 20 % 
change in insulin sensitivity with a power of 80 % at a significance level of 0.05. 
Dropouts were replaced.
 Differences were analyzed by the Student’s t test. Correlation analysis was 
performed by regression analysis. Two-tailed P ≤ 0.05 was considered to denote 
significance. Data are presented as mean ± SEM.
Results
Nineteen of the 32 initially screened subjects underwent randomization and were 
enrolled in the study between June and October of 2009. A total of 13 subjects, 9 
females and 4 males, completed the study. Nine of the 13 subjects who completed 
the study used anakinra in the second treatment period. Two of the 6 drop-outs used 
anakinra in the second treatment period.  Two subjects were discontinued from the 
study due to an infection, one had an H1N1 infection (during anakinra treatment) and 
one had a wound infection (during placebo treatment in the first treatment period). 
Two subjects withdrew due to the physical load of the tests and 2 subjects withdrew 
due to injection site reactions (figure 1). Dropouts were significantly younger (P = 0.008), 
had a higher BMI (P = 0.02) and had a larger waist circumference (P = 0.05) in 
comparison to study subjects that completed the study. All other parameters were 
similar between study subjects that withdrew or completed the study.
 The trial was terminated after the last subject completed all studies in February 
2010. Baseline characteristics of all subjects that completed the study are shown in 
Table 1. BMI did not change during the study.
 Twelve out of 13 subjects experienced local injection site reactions (figure 2B) of 
varying severity. No other adverse events were observed during the study. Sufficiency 
of the intervention was assessed by measuring serum and adipose tissue levels of 
IL-1Ra. The serum levels of IL-1Ra 30 minutes after the last injection of anakinra or 
placebo were 735 ± 86 after anakinra and 0.7 ± 0.1µg/L after placebo, P < 0.001. 
Levels of IL-1Ra in adipose tissue lysates were 29.2 ± 7.5 after anakinra and 1.8 ± 0.4 
ng/L after placebo, corrected for protein levels, P < 0.05. There were no carry-over 
effects detected. Insulin sensitivity of subjects treated with placebo in the first 
anakinra. Biopsies were taken under local anesthesia (2% Lidocaine hcl), from an 
area that was not affected by a local injection site reaction caused by the vehicle of 
anakinra, about 10 cm lateral of the umbilicus using a Hepafix Luer lock syringe 
(Braun, Melsungen, Germany) and a 2.10 x 80 mm Braun medical Sterican needle 
(Braun). The adipose tissue was washed using a 0.9% normal saline solution. The 
adipose tissue was snap frozen and stored at -80 ºC until further analysis or fixated 
in 4% paraformaldehyde for embedding in paraffin.
Immunohistochemistry
An antibody against cluster of differentiation (CD68) (AbD Serotec, Kidlington, UK) 
was used to stain macrophages. Immunohistochemistry was performed as described 
earlier. (19) Macrophage influx was quantified by counting the number of adipocytes 
and macrophages in four representative fields of adipose tissue. A mean number of 
609 ± 24 adipocytes were counted per subject for each treatment period. 
RNA isolation and real-time PCR analysis
Total RNA was extracted from sc adipose tissue using TRIzol reagent (Invitrogen, 
Carlsbad, CA). RNA concentration was determined using the NanoDrop (NanoDrop 
Technologies, Wilmington, MA). cDNA synthesis was performed using the iScript 
cDNA synthesis kit (Bio-Rad Laboratories, Hercules, CA). Real-time PCR was 
performed using Power-SYBR Green master mix and the 7300 real-time PCR system 
(Applied Biosystem, Warrington, UK). Expression of genes was normalized to Beta-2 
microglobulin (β2M) gene expression levels. Used primer sequences were: β2M: AT-
GAGTATGCCTGCCGTGTG (sense), CCAAATGCGGCATCTTCAAAC (antisense), 
peroxisome proliferator-activated receptor γ (PPARγ): ATTGACCCAGAAAGCGAT-
TCC (sense), TCTTCCATTACGGAGAGATCCAC (antisense), Fatty acid binding 
protein 4 (FABP4): AGCACCATAACCTTAGATGGGG (sense), CGTGGAAGTGACG-
CCTTTCA (antisense), Adiponectin: ATCGGTGAAACCGGAGTACC (sense), GCAT-
GTTGGGGATAGTAACGTAA (antisense) 
Biochemical analysis
Glucose concentrations were measured using the oxidation method (Glucose 
Analyser 2; Beckman Instruments Inc., Fullerton, CA). Plasma concentrations of total 
adiponectin, IL-6 , IL-1Ra, high sensitivity C-reactive protein (hsCRP) and Pro-insulin 
were determined using ELISAs(R&D Systems, Minneapolis, MN; Pro-insulin: Millipore, 
Billerica, MA, hsCRP in-house developed ELISA by the University Hospital Maastricht). 
(20) Insulin levels were determined by a radioimmunoassay. For C-peptide 
determination, chemiluminescence was used. Inter- and intra-assay CV’s were 
respectively: adiponectin 2.7 % and 1.3 %; IL6 3.3 % and 5.0 %; IL1-ra 5.0 % and 8.0 
%; hsCRP 4.7 % and 3.8 %; insulin 9.7 % and 4.7 %; pro-insulin 4.7 % and 5.6 %. 
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significantly reduced in study subjects after anakinra treatment. Circulating IL-6 levels 
were below the detection limit of our assay (3 ng/l) for almost all patients in both 
treatments.
treatment period was not significantly different from insulin sensitivity of subjects 
receiving placebo in the second treatment period (2.4 x 10-2 ± 0.3 x 10-2 vs. 2.7 x 10-2 
± 0.5 x 10-2 µmol kg-1 min-1  pmol-1,  P = 0.59).
Systemic inflammation
Inasmuch IL-1Ra has been attributed with anti-inflammatory effects, (21) we measured 
several markers indicative of systemic inflammation. HsCRP levels (anakinra 3.57 ± 
1.40 vs. placebo 5.37 ± 1.78 mg/L, P = 0.05) (figure 3A) and leukocyte counts 
(anakinra 5.32 ± 0.41 vs. placebo 6.39 ± 0.57 x 109/L, P = 0.002) (figure 3B) were 
Table 1   Baseline characteristics of the participants.
Characteristic
Age 53.6 ± 2.8
Sex (male:female) 4 : 9
Body mass index (kg/m2) 33.2 ± 1.3
Waist circumference (cm) 110.5 ± 3.2
Blood pressure (mmHg)
Systolic 143.8 ± 2.8
Diastolic 83.3 ± 2.5
Fasting glucose (mmol/L) 5.49 ± 0.15
HbA1c (%) 5.58 ± 0.09
CRP (mg/L) 5.62 ± 0.08
Hemoglobin (mmol/L) 8.48 ± 0.18
Leucocytes (x109/L) 6.49 ± 0.54
Cholesterol (mmol/L)
Total 5.68 ± 0.32
HDL 1.02 ± 0.07
LDL 3.63 ± 0.30
Triglycerides 2.85 ± 0.50
Interleukin-1Ra (µg/L) 0.76 ± 0.14
HOMA-IR (mmol/pmol)
Medication with anti-inflammatory effects  
(number of study subjects)
simvastatin 20 mg/day
atorvastatin 40 mg/day/
lisinopril 20 mg/day/
aspirin 100 mg/day
5.67 ± 0.64
3
1
Figure 2  Effects of anakinra on insulin sensitivity and adipose tissue.
Insulin sensitivity index after treatment with placebo and anakinra are represented for each 
individual participant, black dashes represent mean values (A). Injection site reaction as 
experienced by one of the participants of the study (B). CD68 staining images of subcutaneous 
adipose tissue of an individual participant after placebo and after anakinra treatment (C). 
Correlation of the change in insulin sensitivity index after anakinra treatment compared to placebo 
with the severity of  macrophage infiltration into the adipose tissue after anakinra treatment 
compared to placebo (D).
A
C
D
B
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for a somewhat enhanced beta-cell function. However, other parameters indicative 
for beta-cell function including stimulated C-peptide levels (AUC during the OGTT) 
(figure 3D) and fasting pro-insulin-insulin ratio (figure 3E) did not differ significantly 
between placebo and anakinra treatment. Raw OGTT-data are represented in figure 4.
 Based on OGTT-criteria, 5 of the study participants had impaired glucose 
tolerance. In this group no statistically significant differences in insulin sensitivity or 
Beta-cell function were found, maybe based on the small sample size.
 No significant differences in triglycerides, HDL-cholesterol, LDL-cholesterol and 
total cholesterol  were present between placebo and anakinra treatment. 
Adipose tissue
The systemic low-grade inflammatory reaction characteristic for obesity is mainly 
inflicted by inflammation in the adipose tissue. (3) The inhibition of IL-1 by IL-1Ra 
(active substance of anakinra) is expected to reduce this inflammatory reaction. 
However the vehicle (citrate), which is used to lower the pH of the solution preventing 
aggregation of anakinra, is known to induce an injection site reaction during the first 
weeks of treatment in a majority of patients. (16) We performed fat biopsies to study 
the local effects of anakinra treatment in abdominal subcutaneous adipose tissue.
 Anakinra treatment led to a high number of infiltrating cells into the subcutaneous 
adipose tissue of various study subjects. Immunohistochemical visualization of 
macrophages using CD68-staining revealed an increased number of macrophages 
in the adipose tissue after anakinra treatment (0.28 ± 0.05 vs. 0.11 ± 0.01 
macrophages per adipocyte, P = 0.005) (figure 2C). In addition, IL-6 concentrations 
in adipose tissue tended to be higher after anakinra treatment (anakinra 26.9 ± 12.4 
µg/g adipose tissue vs. placebo 5.7 ± 1.2 µg/g adipose tissue, P = 0.07) suggestive Insulin sensitivity and Beta-cell function
Although participants were clearly insulin resistant as illustrated by an insulin 
sensitivity index of 2.4 x 10-2 ± 0.3 x 10-2 µmol kg-1 min-1  pmol-1 insulin after placebo 
treatment (normal range in lean subjects 4.0-7.0 x 10-2 µmol kg-1 min-1  pmol-1 insulin, 
(22) treatment with anakinra for 4 weeks did not result in an improvement in insulin 
sensitivity (anakinra 2.8 x 10-2 ± 0.5 x 10-2 vs. placebo 2.4 x 10-2 ± 0.3 x 10-2 µmol kg-1 
min-1  pmol-1 insulin, P = 0.15) (figure 2A). Average HbA1c (anakinra 5.57 ± 0.11 vs. 
placebo 5.62 ± 0.08 %, P = 0.35) and fasting glucose (anakinra 5.34 ± 0.13 vs. 
placebo 5.46 ± 0.15 mmol/L, P = 0.17) levels were unchanged after anakinra 
treatment. Inasmuch no stable isotopes were used during the clamp, we were unable 
to determine effects of anakinra treatment on liver insulin sensitivity levels. Alternatively, 
liver insulin sensitivity was estimated by using data obtained during the OGTT. (23) 
Liver insulin sensitivity  was not different between placebo versus  anakinra treatment 
(P = 0.66).
 The disposition index during the OGTT (change in insulin (0-30 min)/change in 
glucose (0-30 min)) improved after anakinra treatment, P = 0.04 (figure 3C) suggestive 
Figure 3  Effect of anakinra on inflammation and beta cell function.
HsCRP (A) and leukocyte count (B) after treatment with placebo and anakinra. Disposition 
index, calculated as the change in circulating insulin concentration during the first 30 minutes 
of the oral glucose tolerance test, divided by change in circulating glucose concentration 
during the first 30 minutes of the oral glucose tolerance test (C). Area under the curve for 
C-peptide during the oral glucose tolerance test (D). Fasting pro-insulin-insulin ratio (E).
Data are represented as mean ± SEM *P < 0.05 **P < 0.01.
Figure 4  Oral glucose tolerance test data.
Glucose (A), Insulin (B) and C-peptide (C) excursion during the oral glucose tolerance test. 
Data are represented as mean ± SEM.
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Beta-cell function. (10) Another animal study using 1400.24.17 (anti-IL-1β antibody) 
showed reduced HbA1c after 18 weeks of treatment, without consistent improvements 
in insulin sensitivity and glucose tolerance. (24) An important difference between the 
animal studies versus the human trial of Larsen et al. and our trial is the use of specific 
anti-IL-1β antibodies in the animal trials. The human trials do use IL-1RA, which has 
effects on both IL-1α and IL-1β. 
 There are a number of explanations for the lack of improvement in insulin sensitivity 
in our study. 
First, circulating levels of IL-1Ra in study participants may vary considerably. It has 
been suggested that IL-1Ra levels at baseline determine the effects of anakinra 
treatment, with those with the lowest level showing the highest response. (25) 
Nevertheless, in our study we were unable to find any association between IL-1Ra 
levels at baseline and changes in insulin sensitivity after anakinra treatment, which 
largely excludes the possibility that insufficient production of IL-1Ra contributes to the 
development of insulin resistance in our study subjects. Noticeably, also in our 
population baseline IL-1Ra levels were quite variable.
Secondly, the dose of IL-1Ra used in our study or infiltration into target tissues may 
have been insufficient. However, the dosage used in our study was 1.5 times higher 
than normally used and concentrations of IL-1Ra in the circulation were 1000-fold 
higher compared to placebo treatment, accompanied by a 16-fold increase in IL-1Ra 
levels in adipose tissue after anakinra treatment. Moreover, the reduction in 
inflammatory markers including hsCRP and leucocytes suggest that treatment with 
anakinra did provoke a systemic anti-inflammatory effect and was effective.
Thirdly, as adipose tissue is a causative factor for systemic low grade inflammation 
during the development of obesity (3) and is partly responsible for determining 
systemic insulin sensitivity, we evaluated local effects of anakinra in adipose tissue 
biopsies. Based on earlier results of in vitro studies that demonstrated lower insulin 
sensitivity and reduced levels of the adipogenic markers PPARγ and FABP4 after IL-1β 
treatment of adipocytes, we hypothesized that inhibiting IL-1-signaling by anakinra 
treatment would enhance adipogenic gene expression levels. (8, 26) In contrast, 
anakinra treatment led to reduced gene expression levels of PPARγ and FABP4 and 
increased levels of macrophage infiltration. This finding is surprising since treatment 
with anakinra reduced systemic levels of inflammation. The influx of macrophages, 
probably accompanied by other immune cells, is most likely not the direct effect of 
IL-1Ra but might be the effect of one of the additives present in the commercial 
preparations of anakinra. Injection site reaction is a well-known side effect of anakinra 
during the first weeks of treatment and is known to result in the infiltration of 
of an enhancement in inflammatory properties of the adipose tissue. Moreover, 
expression levels of the adipogenic genes PPARγ, FABP4 and Adiponectin determined 
by quantitative PCR analysis in subcutaneous adipose tissue revealed significantly 
decreased levels of PPARγ (P = 0.03) and FABP4 (P = 0.04), whereas Adiponectin 
tended to decrease (P = 0.07) after anakinra treatment.
 The analysis of the macrophage influx into the adipose tissue after anakinra 
treatment revealed a wide distribution in severity among study subjects ranging from 
no influx up to a 12-fold increase in macrophage content of the adipose tissue. The 
severity of the inflammatory reaction in the abdominal subcutaneous adipose tissue, 
reflected by the number of infiltrating macrophages after anakinra treatment, was 
negatively correlated with the difference in individual subject insulin sensitivity  level 
after anakinra treatment (R2 = 0.46, P = 0.01) (figure 2D).
 Subgroup analysis using an increase in macrophage influx of over 300% after 
anakinra treatment as a cut-off point, unveiled that in study subjects with low levels 
of infiltrating macrophages, insulin sensitivity after anakinra treatment improved 
significantly by 39 ± 9 % (95 % CI = 18 – 61 %, P = 0.003) compared to placebo, 
while in subjects with more than a threefold increase in infiltrating macrophages, 
insulin sensitivity decreased by -14 ± 12 % (95 % CI = -47 – 19 %, P = 0.31). 
The average insulin sensitivity of subjects with low macrophage influx was 53% 
(95% CI = 20 – 86 %, P = 0.006) better as compared with subjects with high 
macrophage influx. Levels of circulating hsCRP were comparable in both groups 
(< 300 % increase in infiltrating macrophages 2.49 ± 1.35 vs. > 300 % increase in 
infiltrating macrophages 5.29 ± 0.71 mg/L, P = 0.35). Adipose tissue IL-6 appeared 
lower in subjects with no or mild infiltration of macrophages compared to the subjects 
with extensive infiltration although the differences did not attain statistical significance 
(13.7 ± 5.9 vs. 53.2 ± 34.4 µg/g adipose tissue, P = 0.14).
Discussion
The present study did not find an improvement in insulin sensitivity after four weeks 
of treatment with the IL-1 receptor antagonist anakinra in an insulin resistant 
population. The selected study population enabled us to analyze the effects of an 
anti-inflammatory intervention on insulin sensitivity without the potential interference 
of anti-diabetic medication and the confounding effects of changing glycemic control.
In accordance with earlier findings in a population of type 2 diabetic patients, (15) 
were we unable to detect an improvement in insulin sensitivity after anakinra treatment 
in our study population. However, an animal study using XOMA 052 (anti-IL-1β 
antibody) has reported a positive effect both on insulin sensitivity as well as on 
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findings are in line with the results of the study performed by Larsen et al. The fact that 
we did not find a clear improvement in insulin secretion may be explained by the 
differences in study population. The subjects included in our study were non-diabetic 
and had normal levels of HbA1c and fasting glucose at baseline and had no indication 
of defective beta-cell function, whereas Larsen et al. included patients with type 2 
diabetes mellitus. 
 The dose and duration of treatment were different in our study as compared to 
Larsen et al. (100 mg sc once daily for 13 weeks by Larsen et al. vs. 150 mg sc once 
daily for 4 weeks in our study). The larger dose and shorter treatment period used in 
our study may have aggravated the injection site reaction since adverse effects are 
dose dependently and vanish after prolonged treatment. (16) Theoretically, a 
prolonged treatment of subjects in our study could have resulted in waning of side 
effects – since injection site reactions of anakinra do disappear after 4 to 6 weeks of 
treatment – and may have revealed an improvement in insulin sensitivity. However, a 
prolonged treatment period would substantially extend the duration of the (cross-over) 
trial, increasing the risk for carry-over effects, while biological effects of IL-1 blockade 
were expected to be present within weeks.
In summary, the results of this study do not support the concept that blockade of IL-1 
by anakinra treatment improves insulin sensitivity. It cannot be fully excluded, though, 
that potentially positive effects on insulin sensitivity are (partly) offset by local 
inflammatory reactions at the injection site of anakinra. Whether treatment with other 
modalities that block IL-1 but do not produce local injection site effects potentially has 
a beneficial effect on insulin sensitivity remains to be determined. The present study 
results support a beneficial effect of blocking IL-1 on beta-cell function.
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macrophages. (27) Earlier studies have demonstrated the importance of infiltrating 
macrophages in the subcutaneous adipose tissue in provoking systemic insulin 
resistance. (28) The lack of positive findings of our study on insulin sensitivity may 
thus (partly) be explained by negative effects of local adipose tissue inflammatory 
injection site reactions on insulin sensitivity. In line with this explanation, the severity 
of the inflammatory reaction caused by the injection site reaction in subcutaneous 
adipose tissue turned out to be inversely correlated with the improvement in systemic 
insulin sensitivity after anakinra treatment. 
 The relation between IL-1, inflammation in adipose tissue and its effect on 
systemic insulin sensitivity by affecting systemic inflammation is well known. However 
in this study local inflammation in the abdominal subcutaneous adipose tissue is 
correlated with systemic insulin sensitivity, without influencing systemic inflammation. 
This can partly be explained by a direct negative effect of local inflammation on the 
local adipose tissue. Alternatively, the inflamed adipose tissue might have led to an 
altered adipokine secretion profile that negatively interfered with insulin sensitivity in 
peripheral organs including liver and muscle.
 It should be stressed that the adipose tissue biopsy was not taken out of an area 
with macroscopic inflammation. However, because injection sites were varied over 
time (as advised) over different abdominal areas, the diffuse inflammation observed 
may reflect tissue responses from earlier injections. 
Finally, the hypothesis may be wrong and IL-1 may have no relationship with insulin 
resistance associated with obesity and the metabolic syndrome. Given the many 
supporting observations suggestive for a role of IL-1 in the inflammatory response 
linked to obesity, (29) this explanation seems less likely.
In respect to beta-cell function we found a hint towards improved insulin secretion 
capacity as reflected by the disposition index, although the other evaluated 
parameters for beta-cell function did not improve significantly. However disposition 
index is known to be an independent predictor for the development of type 2 diabetes 
mellitus. (30) It should also be stressed that the participants in this study were 
selected for insulin resistance (obesity/metabolic syndrome) but not insulin secretion 
deficits. All subjects had glucose levels in the non-diabetic range. 
This is the first study that has specifically studied the effects of IL-1 blockade on 
insulin sensitivity in human non-diabetic subjects. A similar study has been performed 
in subjects with type 2 diabetes. (15) This latter study measured both insulin sensitivity 
and insulin secretion before and after 13 weeks of treatment. Glycemic control 
improved after 4 and 13 weeks of treatment and this was attributed to an improvement 
in beta-cell function while insulin sensitivity appeared to be unchanged. As such, our 
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Introduction
The upsurge in the prevalence of obesity has fuelled a rapid increase in the prevalence 
of type 2 diabetes mellitus worldwide. This is explained by the fact that insulin 
resistance associated with obesity leads to a more rapid exhaustion of beta-cell 
function. There is strong evidence that low-grade inflammation is involved in the 
pathogenesis of obesity-induced insulin resistance. 
 One of the key mechanisms involved in obesity-associated inflammation, at least 
at the level of the adipose tissue, is activation of the inflammasome and release of the 
potent cytokine IL-1β.(1-4) High levels of glucose are known to promote a pro-inflam-
matory state.(5-8) Since it is a well-known fact that chronically elevated glucose levels 
induce insulin resistance, that is reversible upon installation of normoglycemia, an 
enhanced inflammatory state may underlie this phenomenon.(9, 10)
 Low grade, systemic inflammation also appears to play a pivotal role in the 
pathophysiology of beta-cell toxicity and progressive beta-cell failure associated with 
diabetes.(11) Similarly, chronically elevated glucose levels further deteriorate beta-cell 
function.(12-14)
 These lines of evidence suggest that interventions aimed at reducing inflammation 
in general and IL-1-activation in particular may both improve insulin sensitivity and 
insulin secretion. Indeed, blocking IL-1 in patients with type 2 diabetes mellitus using 
recombinant human IL-1 receptor antagonist (IL-1Ra) anakinra has been shown to 
improve glycemic control.(15) A study using an anti-IL-1β antibody to block IL-1β 
action reported an improvement in glycemic control in animals, paralleled by an 
enhancement in beta-cell function and insulin sensitivity.(16) However, other 
intervention trials using specific anti-IL-1b antibodies were not consistently reporting 
positive effects on glycemic control.(17-19) In obese, insulin-resistant individuals, we 
found evidence for an improved beta-cell function after anakinra treatment, but could 
not confirm an effect on insulin sensitivity after blockade of IL-1 signaling. 
 It should be noted that any change in glycemic control in patients with type 2 
diabetes will affect glucose toxicity and hence both insulin resistance and beta-cell 
function. In this regard, any change in insulin sensitivity leading to lower glucose 
levels could result in improved beta-cell function.
 We hypothesized that the involvement of IL-1β in obesity-associated insulin 
resistance may be mostly pronounced under conditions of chronic hyperglycemia. 
To assess this hypothesis, we studied the effect of the interleukin-1 receptor antagonist 
anakinra on insulin sensitivity in subjects with longstanding type 1 diabetes that 
displayed a “type 2 phenotype”. Given the fact that beta-cell function is absent in 
these patients, this experimental approach has the advantage that any change in 
insulin resistance will immediately translate to lower glucose levels and lower insulin 
need.
Abstract
Inflammation associated with obesity is involved in the development of insulin 
resistance. We hypothesized that anti-inflammatory treatment with the Interleukin-1 
receptor antagonist anakinra would improve insulin sensitivity.
In an open label proof-of-concept study, we included overweight patients diagnosed 
with type 1 diabetes with an HbA1c level over 7.5 %. Selecting insulin resistant patients 
with longstanding type 1 diabetes allowed us to study effects of anakinra on insulin 
sensitivity. Patients were treated with 100 mg anakinra daily for one week. Insulin 
sensitivity, insulin need and blood glucose profiles were measured before, after one 
week and after four weeks of follow-up.
Fourteen patients completed the study. One week of anakinra treatment led to an 
improvement of insulin sensitivity, an effect that was sustained for four weeks. 
Similarly, glucose profiles, HbA1c levels and insulin needs improved.
In conclusion, one week of treatment with anakinra improves insulin sensitivity in 
patients with type 1 diabetes.
Keywords
Type 1 diabetes, anakinra, Interleukin 1, Insulin Sensitivity, Inflammation, Adipose 
tissue
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Materials and methods
2.1 Study design
Overweight patients with type 1 diabetes mellitus were included in this open-label 
proof-of-concept study. Patients were recruited from the outpatient clinic of the 
Radboud University Nijmegen Medical Centre. We treated patients with anakinra at 
100 mg subcutaneous for eight consecutive days. Study medication was self-admin-
istered once daily. Anakinra was purchased from the regular manufacturer (Swedish 
Orphan Biovitrum). Notably, the study was performed completely independent from 
any company.
2.2 Participants
The institutional ethics review board approved the study. Written informed consent 
was obtained from all subjects.
 Inclusion criteria were type 1 diabetes mellitus for more than five years, body 
mass index higher than 25 kg/m2, insulin requirement > 0.5 U/kg bodyweight per 
day, HbA1c > 7.5% (58 mmol/mol), and age between 18 and 65 years.
 Exclusion criteria were immunodeficiency or immunosuppressive treatment, 
current use of anti-inflammatory medication (100 mg or less of aspirin per day was 
allowed), signs of current infection or treatment with antibiotics, a history of recurrent 
infections or tuberculosis, pregnancy or breast feeding, a serum alanine aminotrans-
ferase or aspartate aminotransferase level of more than three times the upper limit of 
the normal range, a serum creatinine level higher than 130 µmol/l, neutropenia (a 
leukocyte count of less than 2x109/l), or the presence of any other medical condition 
that might interfere with the current study protocol. Participants unable to give 
informed consent were also excluded.
2.3 Study procedures
Immediately before the first injection, directly after the last injection and four weeks 
after the last injection of anakinra we performed an euglycemic hyperinsulinemic 
clamp (insulin infusion rate 360 pmol/m2/min)(20) and obtained a subcutaneous fat 
biopsy. All study procedures were performed after an overnight fast. Patients were 
requested to record glucose levels and insulin use as usual, but as a minimum the 
two days before start of study medication, during the intervention, and four weeks 
after the last treatment with anakinra.
2.4 Subcutaneous adipose tissue biopsy
A subcutaneous adipose tissue biopsy was taken from the abdominal region just 
before the clamp, about 30 minutes after a subcutaneous injection with anakinra. 
Biopsies were taken under local anesthesia (2% Lidocaine hcl), from an area about 
Our results provide in vivo evidence in humans for an insulin sensitizing effect of IL-1 
blockade in the presence of hyperglycemia, inflammation and insulin resistance.
Table 1   Baseline characteristics of the participants.
Characteristic
Age (years) 47 ± 9
Sex (male:female) (9:5)
30.9 ± 13.1Diabetes duration (years)
Body mass index (kg/m2) 31.7 ± 4.6
Blood pressure (mmHg) 133 ± 13 / 76 ± 9
Fasting glucose (mmol/L) 9.45 ± 2.81
HbA1c (% (mmol/mol)) 8.61 ± 0.70 (70)
Insulin regimen (basal-bolus:continuous subcutaneous insulin 
infusion) 6:8
Insulin dose (U/day) 78.6 ± 32.9 
C-reactive protein (mg/L) 1.97 ± 2.85
Leucocytes (x109/L) 5.96 ± 2.20
Neutrophiles (x109/L) 3.76 ± 1.72
Interleukin-1Ra (ng/L) 359 ± 221
Cholesterol (mmol/)
Total
HDL
LDL
Triglycerides
4.37 ± 0.65
1.25 ± 0.37
2.69 ± 0.53
0.96 ± 0.10
Diabetes complications
Macrovascular
Nephropathy
Polyneuropathy
Retinopathy
1
2
7
9
Medication with potential anti-inflammatory effects  (number of patients)
Acetylsalicylic acid 38 mg/day
Acetylsalicylic acid 100 mg/day
Perindopril 8 mg/day
Enalapril 20 mg/day
Enalapril 40mg/day
Fosinopril 20 mg/day
Irbesartan 300 mg/day
Atorvastatin 40 mg/day
Rosuvastatin 5 mg/day
Simvastatin 20 mg/day
Simvastatin 40 mg/day
1
2
1
2
1
1
1
1
1
1
1
Baseline characteristics are reported as mean ± standard deviation.
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Results
3.1 Study population
A total of 14 patients were recruited from the outpatient clinic and enrolled in the trial. 
All patients completed the trial. Clinical characteristics of the study population are 
provided in Table 1. Patients had longstanding type 1 diabetes mellitus, were mostly 
obese, had suboptimal diabetes control, and relatively high insulin needs. Fasting 
C-peptide levels were below the detection limit of the assay (0.03 nmol/l) in all patients 
except for one patient who had a C-peptide level of 0.04 nmol/l, both before and after 
the intervention. Medication, other than insulin, was continued during the study.
 No serious adverse events were observed during the trial. One patient reported 
painful injections of the study medication. Adipose tissue IL-1Ra concentrations were 
significantly higher directly after the intervention, and had returned to baseline values 
4 weeks after the intervention (baseline 1339 ± 347 µg/l vs. directly after 3980 ± 416 
µg/l, P < 0.01 and vs. four weeks after the intervention 1942 ± 476 µg/l, P = 0.54) 
(figure 1).
3.2 Systemic inflammation
As the insulin sensitizing action of anakinra is mediated by a reduction of the 
inflammatory status, several inflammation markers were measured. Leukocyte and 
neutrophil counts were significantly reduced during the intervention, an effect that 
was sustained for up to 4 weeks (figure 2a and b). No differences were found in 
systemic levels of C-reactive protein (figure 2c), IL-1α, IL-6, IL-8, IL-18, TNFα and serum 
amyloid A. IL-1β was not detectable systemically. Serum adiponectin levels did not 
change during anakinra treatment. 
10 cm lateral of the umbilicus using a Hepafix Luer lock syringe (Braun, Melsungen, 
Germany) and a 2·10 x 80 mm Braun medical Sterican needle (Braun). Adipose tissue 
was washed using a 0.9% normal saline solution. The adipose tissue was snap frozen 
and stored at -80 ºC until further analysis, or it was fixed in 4 % paraformaldehyde for 
embedding in paraffin.
2.5 Immunohistochemistry
An antibody against CD68 (AbD Serotec, Kidlington, UK) was used to stain macro - 
phages. Immunohistochemistry was performed as described earlier.(21) Macrophage 
influx was quantified by counting the number of adipocytes and macrophages in ten 
representative fields of adipose tissue. A mean number of 205 ± 6 adipocytes were 
counted per subject for each biopsy.
2.6 Biochemical analysis
Glucose concentrations were measured using the oxidation method (Biosen C-Line; 
EKF-diagnostic GmbH, Barleden, Germany). Concentrations of IL-1Ra, IL-8, serum 
amyloid A and adiponectin were determined using ELISAs (R&D Systems, Minneapolis, 
MN and serum amyloid A: Hycult Biotech, Plymouth Meeting, PA). HsCRP was 
measured by in-house developed ELISA by University Hospital Maastricht (22). IL18 
was determined using magpix (Bio-Rad laboratories Inc, Hercules, Ca). Insulin levels 
were determined by a radioimmunoassay. Inter- and intra-assay CV’s were respectively: 
IL1-ra 5.0% and 8.0%; IL-8 7.4 % and 5.6%; hsCRP 4.7% and 3.8%, adiponectin 4.3% 
and 2.4%; IL-18 7% and 5%; insulin 9.7% and 4.7%.
Measurements of other parameters were performed in the clinical laboratory unit of 
the Radboud University Nijmegen Medical Centre.
2.7 Statistical analysis
We considered a 15 % improvement of the primary endpoint, insulin sensitivity, as 
determined by euglycemic hyperinsulinemic clamp, as clinically relevant. Assuming 
a test-to-test correlation coefficient of 0.5 (paired tests) and a mean glucose infusion 
rate of 45.7 ± 8.5 µmol/kg/min(10), would require a total of 12 subjects to detect a 15 
% change in insulin sensitivity with a power of 80 % at a significance level of 0.05. 
Taking into account the technical difficulties that are frequently experienced when 
performing euglycemic clamps, we included 14 subjects in our study. Dropouts were 
replaced. Differences were analysed by the Student’s t test. Correlation analysis was 
performed by regression analysis. Two-tailed P ≤ 0.05 was considered to denote 
significance. Data are presented as mean ± SEM.
Figure 1  Interleukin-1 Receptor Antagonist concentrations.
IL-1Ra levels in adipose tissue before, during (directly after the last injection) and after (4 weeks 
after the last injection) anakinra treatment.
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3.3 Fat biopsies
To quantify local inflammation induced by anakinra injection (a well-known side effect 
of one of the solvents) fat biopsies were taken. Macrophage numbers in fat tissue 
were counted using an immuno-histochemical approach. The number of macro - 
phages did not significantly change during or after the intervention. (figure 2d and e).
Figure 2  The effects of anakinra on inflammation.
Serum levels of leukocytes (A), neutrophils (B) and HsCRP (C),  before, during (directly after the 
last injection) and after (4 weeks after the last injection) anakinra treatment. Number of 
macrophages per adipocyte in subcutaneous adipose tissue biopsy before, during (directly 
after the last injection) and after (4 weeks after the last injection) anakinra treatment (D and E).
Figure 3  The effects of anakinra on insulin sensitivity and glycemic control.
Insulin sensitivity as determined by euglycemic hyperinsulinemic clamp before, during and 
after anakinra treatment (A). HbA1c before, during (directly after the last injection) and after (4 
weeks after the last injection) anakinra treatment (B). Glucose levels during the day as reported 
by patients before, during (directly after the last injection) and after (4 weeks after the last 
injection) anakinra treatment (C). Amount of insulin per kilogram bodyweight used by patients 
before, during (directly after the last injection) and after (4 weeks after the last injection) anakinra 
treatment (D). Change in systemic leukocyte counts (E) and systemic neutrophil counts (F) 
correlated with change in insulin sensitivity, black lines represent linear regression analysis.
Data are reported as mean ± standard error of the mean, * P < 0.05, ** P < 0.01.
A
C
A
C
E
E
B
B
D
F
D
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glucose control. However, this direct effect on the beta-cell cannot be the explanation 
in our study performed in patients with type 1 diabetes, as by definition these patients 
have no residual beta-cell function. 
 Earlier trials using anakinra  in humans did not detect improvements in insulin 
sensitivity. In the trial of Larsen et al. that used euglycemic-hyperinsulinemic clamp 
studies performed in a subgroup of patients and an analysis of the insulin-sensitivity 
index by the homeostasis model assessment (HOMA), did not reveal any difference 
after anakinra as compared to placebo treatment.(15) The same holds true for our 
previous trial in which glucose disposal rates were not significantly different between 
anakinra and placebo treatment.(24) The lack of effect of anakinra on insulin sensitivity 
in these earlier studies may partially be explained by injection site reactions that are 
a well-known adverse event affecting a large percentage of treated patients. The 
reaction is transient and is caused by one of the solvents for solution for injection of 
anakinra.(25) Indeed, in our previous trial that included four weeks of treatment with 
anakinra, an inverse correlation between the number of macrophages in the 
subcutaneous adipose tissue caused by injection site reactions and the improvement 
in systemic insulin sensitivity levels was observed.(24) A recent study in mice showed 
a direct link between adipose tissue macrophages and bone marrow myeloid 
progenitor proliferation. Treatment with anakinra resulted in decreased leukocyte 
production, fewer adipose tissue macrophages and improved glucose tolerance.(26) 
 Because of the design of the current trial, in which the dose of anakinra was 
reduced by 33% and the treatment period was reduced by 75% in comparison to our 
earlier trial, results were less likely to be influenced by a pro-inflammatory reaction in 
the subcutaneous adipose tissue. Indeed, patients in this trial did not suffer from an 
enhancement in local inflammatory status, as the number of infiltrating macrophages 
in the subcutaneous abdominal adipose tissue did not significantly change after the 
intervention period. Furthermore no injection site reactions were recorded. Although 
we are not informed about the effect of anakinra on the inflammatory status of the 
visceral adipose tissue it appears reasonable to expect that an increase in 
inflammatory status of the subcutaneous abdominal adipose tissue blurs a potential 
effect of long term (more than one week) anakinra treatment on insulin sensitivity, as 
50% of patients treated with anakinra reported such an adverse event.(15) 
 A second reason for the difference in findings is that our previous trial consisted 
of non-diabetic subjects, and hence hyperglycemia was not involved. Since glucose 
toxicity induces insulin resistance, anakinra may especially reduce the insulin 
resistance associated with high glucose levels, which is in agreement with earlier 
results showing that glucose toxicity is partly mediated by IL-1β.(27-29)
 Finally, our study population existed of patients diagnosed with type 1 diabetes 
mellitus. Endogenous levels of IL-1Ra in patients with type 1 diabetes mellitus are reported 
to be lower in comparison to patients with type 2 diabetes mellitus.(30) Hence, 
3.4 Insulin sensitivity and glycemic control
At baseline, subjects were moderately insulin resistant. Insulin sensitivity as 
determined by the glucose infusion rate (euglycemic hyperinsulinemic clamp), was 
34.5 ± 3.7 µmol kg-1 min-1 (reference value for lean individuals is 53.9 µmol kg-1 min-1). 
(23) During treatment with anakinra, insulin sensitivity numerically increased to 39.2 
± 4.0 µmol kg-1 min-1, although this change did not attain statistical significance, but 
the improvement was persistent and significant four weeks after the last administration 
of anakinra (insulin sensitivity 39.2 ± 3.2 µmol kg-1 min-1, P = 0.02) (figure 3a). HbA1c 
levels four weeks after termination of anakinra treatment were in accordance with 
the results of the clamps and dropped from baseline 8.61 ± 0.19% (71 mmol/mol) 
to 8.34 ± 0.16% (68 mmol/mol), P < 0.01) (figure 3b).
 Improved glycemic control was also shown by a decrease in mean glucose 
levels from 9.71 ± 0.45 mmol/l at baseline, to 8.33 ± 0.40 mmol/l during anakinra 
usage (P < 0·01) and to 8.34 ± 0.55 mmol/l after termination of the anakinra 
intervention (P = 0.04) (figure 3c). The improved glycemic control was achieved with 
a lower requirement of insulin. At baseline, average insulin usage was 78.6 ± 8.8 U/day, 
during anakinra treatment the patients used 66.9 ± 6.5 U/day and remained lower 
four weeks after the last injection of anakinra (69.7 ± 7.2 U/day) (figure 3d).
 The improvement in insulin sensitivity appeared to be associated with the anti- 
inflammatory efficacy of anakinra treatment since the enhancement in insulin 
sensitivity levels correlated with the reduction in leukocyte (R2 = 0.39, P = 0.02) 
(figure 3e) and neutrophil counts (R2 = 0.47, P < 0.01) (figure 3f) directly after the 
treatment.
3.5 Cholesterol
Lipid levels (total cholesterol, HDL-cholesterol, LDL-cholesterol and triglycerides) 
were not significantly different after the intervention compared to baseline.
Discussion
The main finding of our study is that a one week treatment with the IL-1 receptor 
anakinra decreases systemic inflammation and improves insulin sensitivity in insulin 
resistant patients with type 1 diabetes. This change in insulin sensitivity is mirrored by 
better glucose control and decreased insulin needs.
 The demonstration of improved glycemic control with anakinra treatment is in 
line with an earlier study demonstrating a beneficial effect of anakinra in patients with 
type 2 diabetes after 13 weeks of treatment.(15) However, there are also important 
differences between the two studies. Larsen et al. studied patients with type 2 
diabetes and found a beneficial effect on beta-cell function, explaining the improved 
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 In conclusion, this study proves that one week of treatment with the IL-1 receptor 
antagonist anakinra improves insulin sensitivity, an effect that is sustained for at least 
4 weeks. The change in insulin sensitivity is mirrored by lower insulin needs and 
better glucose control. This study strongly suggests involvement of IL-1 in the insulin 
resistance associated with the combination of obesity and hyperglycemia. Although 
some lack of consistency in the outcome of previous studies focused on effects of 
anakinra treatment in patients with diabetes exists, our results argue for beneficial 
effects of IL-1 inhibition in specific groups of patients. Hence, future studies should 
focus on the identification of patients that may for example have low endogenous 
levels of IL-1ra, high circulating levels of pro-inflammatory markers or diabetes for 
more than five years and therefore particularly benefit from anakinra treatment to 
improve glycaemic control. Whether this translates to a chronic treatment approach 
in some subsets of patients (those with pronounced hyperglycemia-associated 
insulin resistance) remains to be determined. 
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treatment with anakinra may be more effective in patients that suffer from low circulating 
levels as compared to patients with higher basal plasma concentrations of IL-1ra.
 Studies testing IL-1β antibodies in humans report positive effects on glycemic 
control.(17, 19) The clinical trial using Gevokizumab does show improvement in 
beta-cell function, but no effects on insulin sensitivity measured by the insulin 
sensitivity index were seen. Canakinumab did not result in improvement in homeostatic 
model of assessment of insulin resistance.  These antibodies are specifically blocking 
IL-1β, while anakinra blocks both IL-1α and IL-1β. Furthermore, the bioavailability of 
these antibodies in the adipose tissue is unknown. In the present study we show a 
clearly increased level of anakinra in adipose tissue during treatment. Besides, the 
studies testing IL-1β antibodies did not focus on insulin sensitivity. The outcome 
measures used are less sensitive in recording changes in insulin sensitivity, as 
compared to the clamp technique used in this study.
 The therapeutic efficacy of anakinra treatment observed in our study may largely 
be the result of a decrease in systemic inflammatory levels, as represented by lower 
leukocyte and neutrophil counts. This is supported by our observation that a decrease 
in leukocyte counts correlates with an improvement in insulin sensitivity. One would 
expect reduced levels in other inflammation parameters like hsCRP, serum amyloid A 
and IL-6 as well. However this was not seen in the current trial. An explanation could 
be the already low inflammatory levels before initiation of the trial. Other explanations 
are the short treatment interval, or an assay failure.  
 Our study has important potential clinical implications. While the current, once 
daily treatment with anakinra is inconvenient and might be complicated with injection 
site reactions, a short period of treatment with IL-1ra, either subcutaneously or i.v., 
may be effective in patients with extreme insulin resistance due to longstanding high 
glucose levels. Here, optimal treatment duration and dose need to be determined.
 Our study has limitations. First of all, this was an open trial and hence cannot 
exclude a study effect. The relatively strong and sustained effect and the correlation 
between improvements in insulin sensitivity and reduction in systemic inflammation 
argue against this possibility. Another possibility that cannot be excluded is that 
patients have changed their dietary or exercise habits that may promote improvements 
in insulin sensitivity. Noticeably, no significant changes in bodyweight were reported 
in any of the study participants during the intervention. Finally, caution should be 
taken when extrapolating the validity of our data in patients with type 1 diabetes and 
obesity to patients with the metabolic syndrome/type 2 diabetes as differences in 
etiology may exist.
 The strength of our study lies in the precisely characterized treatment in a 
carefully selected group of patients. By testing the effects of anakinra in patients 
without residual beta-cell function we were able to rule out secondary effects on 
insulin sensitivity mediated by reduced glucose toxicity.
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Introduction
Type 2 diabetes mellitus occurs when beta cells fail to appropriately increase insulin 
secretion in response to insulin resistance. (1) Beta cell function progressively deteriorates 
over time (2, 3) and inflammation at the level of the beta cell seems to be involved. (4)
 The proinflammatory cytokine interleukin-1 (IL-1) appears to be an important 
mediator in the inflammatory process in the beta cell. In vitro, high glucose levels 
increase beta cell production of IL-1β followed by functional impairment and apoptosis 
of beta cells. Beta cells can be rescued from hyperglycaemia-induced apoptosis by 
addition of the interleukin-1 receptor antagonist (IL-1Ra), a naturally occurring inhibitor 
of IL-1β. (5)
 Blocking the effects of IL-1 in patients with type 2 diabetes mellitus by anakinra, 
a recombinant human IL-1RA, has been shown to improve glycaemic control through 
enhanced beta cell function. (6) However, in patients with diabetes, improvement of 
beta cell function can be either direct or indirect due to improvement in glucose 
levels, since hyperglycaemia itself impairs both insulin secretion and insulin sensitivity 
(concept of glucotoxicity). (7)
Abstract
Inflammation at the level of the beta cell seems to be involved in progressive beta cell 
dysfunction in type 2 diabetes mellitus. We assessed the effect of blocking 
Interleukin-1 (IL-1) by anakinra (recombinant human IL-1 receptor antagonist) on beta 
cell function. 
Sixteen participants with impaired glucose tolerance were treated with anakinra 150 
mg daily for 4 weeks in a double blind, randomized, placebo controlled, cross-over 
study with a wash-out period of 4 weeks. At the end of each treatment period, oral 
glucose tolerance tests (OGTT) and hyperglycaemic clamps were performed. 
First phase insulin secretion improved after anakinra treatment compared to placebo, 
148±20 vs 123±14 mU/l respectively (p = 0.03), and the insulinogenic index was 
higher after anakinra treatment.
These results support the concept of involvement of IL-1β in the (progressive) 
decrease of insulin secretion capacity associated with type 2 diabetes mellitus.
Clinical trials.gov number NCT01285232
Figure 1  Design, enrollment, withdrawal and completion of the trial.
Assessed for eligibility (n=37) 
Excluded (n=19)
- Did not meet inclusion criteria (n=16)
- Diagnosed with type 2 diabetes mellitus (n=3)
Randomized (n=18)
Withdrawn before start of study
medication (n=1)
Received intervention (n=17)
Discontinued intervention due to
injection site reaction (n=1)
Analysed (n=16)
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Statistical analysis 
Statistical analyses were performed using Graphpad 5.0. Differences in means were 
tested by paired Student’s t-test for normally distributed and Wilcoxon signed rank 
test for non-normally distributed data. Results were expressed as mean ±SEM unless 
otherwise indicated. Significance was set at a p-value of less than 0.05. 
Results
A total of 16 participants (7 females and 9 males) completed the trial. (figure 1) 
Baseline characteristics of the participants were (mean±SD): age 55±9 years, BMI 
32±5 kg/m², HbA1c 5.8±0.5 % and fasting glucose level 5.3±0.71 mmol/l. (table 1)
 Leukocyte (anakinra 5.4±0.3 x109/l vs placebo 6.2±0.4 x109/l, p = 0.017) and 
neutrophil counts (anakinra 2.9±0.3 x109/l vs placebo 3.7±0.3 x109/l, p = 0.001) were 
significantly reduced after anakinra treatment, as were CRP levels (anakinra 0.9±0.2 
ug/ml versus placebo 2.7±0.6 ug/ml, p < 0.001).
 First phase insulin secretion improved after anakinra treatment compared to 
placebo (148±20 vs 123±14 mU/l respectively, p=0.03). Second phase insulin 
secretion, insulin response after arginine stimulus and maximal insulin secretion, did 
not differ between the two treatment arms (figure 2).
 We hypothesized that treatment with the IL-1Ra anakinra can improve beta cell 
function subjects with impaired glucose tolerance (IGT).
Materials and methods
Study population
Included were participants with IGT defined as either impaired fasting glucose (IFG) 
(fasting glucose 5.6-6.9 mmol/l) and/or IGT (2 hour plasma glucose 7.8-11.0 mmol/l) 
by 75 g oral glucose tolerance test (OGTT) and/ or hemoglobin A1c (HbA1c) levels of 
5.7-6.4%. (8) Other inclusion criteria were body mass index > 25 kg/m² and age 
40-70 years. 
Study design 
This was a randomized, double-blind, placebo controlled crossover study. Participants 
were randomly assigned to treatment with anakinra 150 mg subcutaneous (sc) once 
daily for 4 consecutive weeks or placebo sc once daily for 4 consecutive weeks. 
After a wash-out period of 4 weeks, participants crossed over to the other treatment 
arm. At the end of each treatment, a hyperglycaemic clamp and a 75 g OGTT were 
performed. The Pharmacy Department provided anakinra and matching placebo 
injections and was responsible for blinding and randomization. 
Hyperglycaemic clamp
The hyperglycaemic clamp procedure was performed after an overnight fast. After a 
30 minute equilibration period, the clamp was started (t=0) by an intravenous bolus 
of 0.8 ml glucose 20% solution per kg body weight followed by a variable glucose 
20 % infusion in order to maintain a blood glucose level of 10 mmol/l for a total 
duration of 120 minutes. At 120 minutes, an arginine bolus of 5 grams was administered 
 to measure maximum insulin secretory capacity.
 Blood glucose levels were measured in whole blood using the oxidation method 
(Biosen C-line, EKF diagnostics, GmbH) every 5 minutes to allow precise adjustment 
of the glucose infusion rate. Blood samples were taken at t= 0, 2.5, 5, 7.5, 10, 20, 
40, 60, 80, 100, 120, 122.5, 125, 127.5, 130 and 150 minutes and for assessment of 
insulin concentration. After 150 minutes of hyperglycaemia, glucose infusion was 
discontinued. 
 The OGTT was performed in the morning after an overnight fast, at least 24 hours 
before or after the hyperglycaemic clamp. After collection of the fasting blood samples, 
the subject drank 75 g of anhydrous glucose in 250-300 ml water over the course of 
5 minutes. Blood samples were collected every 30 minutes for 2 hours after the test 
load. Insulin measurements were performed (Magpix, Luminex) and samples were 
assayed for total glucagon-like peptide-1 (GLP-1) and glucagon. (9)
Table 1   Baseline characteristics (mean±SD).
Characteristic
Age (years) 54.6±8.5
Sex (male:female) 9:7
Weight (kg) 99.0±24.1
BMI (kg/m²) 31.7±4.8
Blood pressure systolic (mmHg) 131±15
Blood pressure diastolic (mmHg) 79±9
Fasting glucose (mmol/l) 5.3±0.7
HbA1c (%) 5.8±0.5
Hemoglobin (mmol/l) 8.6±0.8
Leukocytes  (x109/l) 6.4±1.4
CRP (ug/ml) 3.1±3.7
IL-1Ra (pg/ml) 774±445
Use of antihypertensives 31%
Use of statins 19%
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 Anakinra had no effect on the insulin sensitivity index (2.0±0.3 mmol/mU anakinra 
and 2.4±0.43 mmol/mU placebo treatment, p= 0.29)
 In line with the first phase clamp results, the insulinogenic index derived from the 
OGTT improved after anakinra compared to placebo treatment (14.5±1.7 vs 11.4±1.1 
mU/mmol respectively, p= 0.036). (figure 3)
 Anakinra treatment had no effect on GLP-1 and glucagon levels during OGTT.
 Anakinra treatment did not change fasting glucose levels (5.5±0.2 vs 5.5±0.3 
mmol/l) or HbA1c levels compared to placebo  (5.6±0.1 % vs 5.7±0.1%, p=0.068). 
 Fourteen participants experienced injection site reactions during anakinra treatment. 
One subject withdrew because of the local reaction. All reactions disappeared after 
the cessation of anakinra treatment. One participant developed erysipelas and one 
participant developed a thrombophlebitis of the antecubital vein, which was used for 
infusion of glucose 20% during the clamp, both after anakinra treatment. There were 
no other infections or serious adverse events. 
Figure 2  Hyperglycaemic clamp.
Glucose (A) levels and glucose infusion rate (GIR) during the hyperglycaemic clamp after 
treatment with anakinra (dark grey) and placebo treatment (light grey). The glucose levels are 
depicted as symbols with connecting line and the GIR as symbols only. During the hyper- 
glycaemic clamp, glucose levels were nearly identical in both treatment periods (anakinra 
9.98± 0.04 mmol/l vs placebo 10.02±0.04 mmol/l respectively, p = 0.43). The mean CV of the 
hyperglycaemic clamp was below 4 % in both treatment periods. Insulin (B) levels during the 
hyperglycaemic clamp after treatment with anakinra and placebo.  First phase insulin secretion 
was calculated as the sum of increments of plasma insulin levels from 2.5 to 10 minutes of the 
clamp. First phase insulin secretion after treatment with anakinra (dark grey) and placebo 
treatment (light grey) are shown as insulin levels (C) and as the mean sum of increments (D). 
Second phase insulin secretion (E) was taken as the average increment in plasma insulin levels 
from 80 to 120 minutes of the clamp. The maximal insulin concentration (F)  was the single 
highest post arginine insulin level. The acute insulin response to arginine (∆I arginine) (G) was 
calculated by subtracting as the insulin level at 120 minutes from the mean insulin level of 122.5 
and 125 minutes. Insulin sensitivity was assessed as an insulin sensitivity index (ISI) (H), 
defined as glucose infusion rate (GIR) to maintain hyperglycaemia from 80 to 120 minutes 
divided by the mean plasma insulin level during the same interval. Data are expressed as 
mean±SEM.
Figure 2  Continued.
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Discussion
The main finding of the present study is that four weeks of anakinra treatment 
improves the insulinogenic index and augments the first phase insulin secretion. 
These observations suggest that anakinra can improve beta cell function. However, 
second phase insulin secretion, insulin response after arginine, and the maximal 
insulin concentration were not influenced by anakinra. The improved first phase 
insulin response was not mediated by an enhanced incretin response. 
 These findings are in line with Larsen et al. (6) and with our earlier study in 
non-diabetic subjects with the metabolic syndrome, where anakinra improved the 
disposition index. (10) A recent study using canakinumab, a human monoclonal 
anti-IL-1β antibody, found a trend towards improving insulin secretion rates in patients 
with type 2 diabetes mellitus and an improved insulin secretion in subjects with IGT. 
(11)
 A number of mechanisms may underlie these results. First, anakinra might inhibit 
intra-islet inflammation and thereby preserve beta cell function. In vitro studies show 
that high glucose levels induce IL-1β production by beta cells followed by beta cell 
dysfunction and apoptosis and that these deleterious effects can be prevented by 
IL-1Ra. Second, anakinra may improve beta cell function by decreasing systemic 
inflammation. Elevated levels of IL-1β, CRP and IL-6 are predictive of type 2 diabetes 
mellitus. (12) The reduction in inflammatory markers in our study suggest that anakinra 
treatment induces a systemic anti-inflammatory effect. Third, an improvement in beta cell 
function could be explained by a compensatory response to a decline in insulin 
sensitivity. However, we did not find significant changes in the insulin sensitivity index.
 In summary, our study supports the concept of involvement of IL-1β in the decrease 
of insulin secretion capacity associated with type 2 diabetes mellitus. These findings 
are relevant since improvement in beta cell function can delay and/or prevent 
progression to frank diabetes. 
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Figure 3  Oral glucose tolerance test.
Glucose (A) and insulin (B) levels during OGTT for anakinra (dark grey) and placebo (light grey) 
treatment. The area under the curve (AUC) for glucose during the OGTT did not differ between 
anakinra and placebo treatment, while the AUC for insulin tended to be higher after anakinra 
treatment (321±40 vs 286±41mU*120 min/l, p=0.09). The insulinogenic  index (C) was calculated as 
the increase in insulin level from 0 to 30 minutes divided by the increase in plasma glucose level 
from 0 to 30 minutes. The insulinogenic index was higher after treatment with anakinra 
compared to placebo treatment. The GLP-levels during OGTT (D) and area under the curve for 
GLP-1 (E) are shown for both anakinra (dark grey) and placebo treatment (light grey). Glucagon 
levels during OGTT (F) and area under the curve for glucagon (G) are also depicted.
Data are expressed as mean±SEM.
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Summary
The overall objective of this thesis was to gain more insight in the role of inflammation 
on insulin sensitivity and beta cell function, both key elements in the development of 
type 2 diabetes. Given the complexity of immune responses and the heterogeneity 
of the interaction between the immune system and the host’s metabolism, research 
was focused on several individual components of the immune system. This chapter 
describes the results of the research projects included in the thesis and puts them 
into perspective. 
Although, the link between obesity and type 2 diabetes mellitus is evident, it is unclear 
which exact mechanisms make some individuals more susceptible for developing 
type 2 diabetes mellitus than others. Obesity is characterized by a chronic low grade 
inflammatory state, as reflected by relatively high circulating levels of pro-inflammatory 
parameters. Furthermore, adipose tissue of insulin resistant individuals is characterised 
by large adipocytes and relatively high numbers of pro-inflammatory macrophages 
together with the presence of other pro-inflammatory immune cells from both the 
adaptive and innate immune system. To gain more insight in the mechanisms causing 
obesity induced inflammation it is important to decipher the type of receptors that are 
expressed by the adipose tissue that can function as potential instigators of pro-in-
flammatory responses.
Possible candidates include the Pathogen recognition receptors (PRRs) that are 
indispensable for recognizing danger and pathogen associated molecular patterns 
(DAMPs and PAMPs). When a DAMP or PAMP is recognized by a PRR, an immune 
response is initiated, leading to clearance of the potentially dangerous pathogen or 
dysfunctional cell(s). 
In chapter 2 we describe the expression of different TLRs in adipose tissue. The 
TLR-family is the best-known group of PRRs. TLR-2 and TLR-4 have earlier been 
described to translate the presence of saturated free fatty acids into pro-inflammatory 
cytokine production, similar to LPS recognition. First, we observed that many TLRs 
are expressed in adipose tissue. TLR-3 and TLR-5 were remarkable as their 
expression was significantly higher in the mature adipocyte fraction as compared to 
the non-adipocyte fraction. This pattern was found in subcutaneous as well as in 
visceral adipose tissue. Second TLR-3 expression was induced during differentiation 
of adipocytes. When adipocytes were treated with poly (I:C), an agonist of TLR-3, the 
expression of IL-8 and MCP-1 increased, while adiponectin and PPAR-γ expression 
decreased. All these findings suggested that TLR-3 is functionally active in adipocytes. 
In vivo TLR-3 knock-out mice that were exposed to a high-fat diet (HFD) displayed 
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First we describe in chapter 4 the results of anakinra treatment in obese individuals 
with the metabolic syndrome, but without diabetes mellitus. This group of subjects 
was chosen, as these subjects are likely to be insulin resistant, but do not have 
profound hyperglycemia and do not use glucose lowering medication. In a 
double-blind, placebo-controlled cross-over study, we treated subjects with anakinra 
or matching placebo subcutaneously once daily for 4 weeks. 
 Anakinra significantly decreased systemic inflammation and increased IL-1RA 
levels, but did not affect insulin sensitivity. Anakinra did significantly improve the 
disposition index as calculated from the results of the oral glucose tolerance test, 
compatible with a beneficial effect on beta-cell function. We noted injection site 
reactions in several individuals. Differences in individual insulin sensitivity after 
anakinra and placebo treatment appeared to be inversely correlated with macrophage 
influx in subcutaneous adipose tissue biopsies.
 This study suggests that IL-1receptor blockade with anakinra probably has a 
positive effect on beta-cell function but does not have a clear beneficial effect on 
insulin resistance in obese subjects with the metabolic syndrome. 
 Following the results of the first study described in chapter 4 we hypothesized 
that the potential effect of anakinra treatment on insulin sensitivity may have been 
blurred by a local injection site reaction. Alternatively, the effects may be less 
pronounced in the absence of high glucose levels. 
Therefore we designed a second study described in chapter 5. Here we focussed 
specifically on insulin sensitivity in patients with diabetes. Overweight individuals with 
longstanding type 1 diabetes mellitus were treated with anakinra. As these patients 
have no residual beta-cell function, any improvement in glycemic control has to be 
the result of improvement in insulin sensitivity. Moreover, this group of patients was 
chosen to determine whether anakinra might have an effect on hyperglycemia- 
induced insulin resistance.
 The study design included one week of treatment with a lower dose of anakinra. 
This approach was chosen to reduce the possibly negative effect of injection site 
reactions on insulin sensitivity. The study showed that treatment with anakinra reduced 
systemic leukocyte counts. Insulin sensitivity increased after one week treatment with 
anakinra, which effect persisted in the following four weeks off treatment. Glucose 
profiles, insulin need and HbA1c levels improved similarly. As this study did not 
include a control arm, a study / placebo effect on the primary outcomes cannot be 
excluded, but the fact that the improvement of insulin sensitivity was strongly 
correlated to the decrease in leukocyte and neutrophil count argues against this 
explanation.
unchanged body weight and insulin sensitivity as compared to wildtype animals. 
Inflammation in the adipose tissue was similar as compared to HFD-fed wildtype 
mice. Additionally, TLR-3 expression in adipose tissue was not affected by the HFD 
intervention of 16 weeks.
 In human adipose tissue, TLR-3 expression tended to be negatively correlated 
with IL-8 expression and positively with FABP-4 expression, but not with body weight, 
insulin sensitivity or number of crown-like structures. TLR-3 expression in adipose 
tissue was not correlated with systemic levels of C-reactive protein.
 Altogether, these findings show that TLR-3 is abundantly present in adipose 
tissue and especially in adipocytes. However, absence of TLR-3 in vivo has no, or only 
very modest effects on metabolic functions including insulin sensitivity after 16 weeks 
of HFD-feeding.
IL-1β plays an important role in adipose tissue inflammation and insulin sensitivity in 
general. The IL-1 family member IL-18 has also been shown to have consequences on 
insulin sensitivity. IL-1F6 and IL-1F8 are two novel IL-1 family members. Both are 
pro-inflammatory cytokines, involved in inflammatory processes in skin and lung. 
In chapter 3 we studied whether IL-1F6 and IL-1F8 were present in adipose tissue and 
whether exposure to IL-1F6 and IL-1F8 had effects on adipocytes. IL-1F6 is primarily 
present in the stromal vascular fraction, but was also detected in the mature adipocyte 
fraction. Treatment with LPS induced IL-1F6 expression. IL-1F8 was not detected in 
adipose tissue. Treatment of adipocytes with IL-1F6 significantly reduced PPAR-γ 
expression, while other adipogenic gene expression tended to be lower as well, 
suggestive for induction of insulin resistance of the cell. IL-1F8 did not affect expression 
of adipogenic genes. Both, IL-1F6 and IL-1F8 treatment induced IL-6 and IL-8 gene 
expression in adipocytes suggestive of a pro-inflammatory effect. 
 These findings show that IL-1F6 is present in adipose tissue, in particular in the 
stromal vascular fraction, and that its expression is induced by LPS. Adipocyte 
treatment with IL-1F6 and IL-1F8 has a modest, IL-1-like effect on metabolic and 
inflammatory gene expression. IL-1F8 is not present in adipose tissue. 
As IL-1 is involved in adipose tissue and beta-cell inflammation it may be anticipated 
that IL-1 blockade may improve insulin sensitivity and insulin secretion. This hypothesis 
was tested in three studies, described in Chapter 4, 5 and 6. The effects of treatment 
with the IL-1receptor antagonist (IL-1ra) anakinra were examined in subjects with 
unique clinical characteristics, which made it possible to focus specifically on insulin 
sensitivity and insulin secretion and allowed us to exclude most important confounding 
factors.
 The combined results of these three trials clarify the pathophysiological effects 
of IL-1 mediated inflammation on glycaemic control. 
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Discussion and future perspectives  
The prevalence of diabetes mellitus will increase over the next decades with an 
estimated global prevalence of 9% in 2014 and 592 million people with diabetes in 
2035. (1) Worldwide health care expenditure for diabetes was 548 billion US dollars 
in 2013, 11 % of the total expenditure. (1) The increasing prevalence of diabetes is the 
consequence of the obesity epidemic. The best way to counteract a further increasing 
prevalence of diabetes is to prevent people to become obese. While this sounds 
simple, reality is complex, as food is everywhere and always available and healthy 
food is often relatively expensive. Further, modern society is characterized by 
decreased need for physical activity. Still, the primary goal for (non-) governmental 
organisations aiming to increase public health should be to make healthy food more 
widely available and to promote physical activity.   
Besides this primary goal it is important to unravel the association between obesity 
and insulin resistance. Understanding the pathophysiological basis of diabetes 
mellitus will help us to treat and hopefully prevent the disease. Obesity-induced 
inflammation may be an important link between obesity and diabetes. Obese individuals 
are characterized by elevated levels of inflammatory markers, (2, 3) probably caused 
by an inflammatory response in the adipose tissue. Immune cells, like macrophages 
and T-cells infiltrate adipose tissue of obese individuals. (4, 5) However much remains 
to be learned about the factors that initiate and propagate this inflammatory reaction. 
In this respect we have focussed on toll-like receptors, more specifically TLR-3, and 
the IL-1 cytokine family, which will be discussed in more detail below. 
Toll like receptor 3
In this thesis have we demonstrated that many toll-like receptors are expressed in 
both mature adipocytes and in the stromal vascular fraction of adipose tissue. It was 
already known that TLR-2 and TLR-4 can be activated by saturated fatty acids and 
induce a pro-inflammatory response. Given the abundant expression of TLR-3 in 
mature adipocytes, TLR-3 may also be of importance in determining the link between 
obesity and inflammation. We showed that TLR-3 activation in adipocytes indeed 
results in an inflammatory response, reduced adipocyte differentiation and inhibition 
of insulin signalling. (6, 7) However, in vivo did we neither find an effect on insulin 
sensitivity, nor on obesity-induced inflammation. These findings are in contrast to a 
study, which tested a more extreme high-fat diet, over a longer time-interval in a 
TLR-3 knockout model and showed improved glucose tolerance and protection 
against liver steatose. (8) This disconcordance may imply that TLR-3 exerts different 
effects between liver and adipose tissue. The expression of TLR-3 in mature 
adipocytes in comparison to stromal vascular fraction is less prominent in mice than 
In chapter 6 we determined effects of anakinra on beta-cell function in more detail. 
Here, we recruited subjects with impaired glucose tolerance, but without diabetes 
mellitus. As these patients do not have diabetes mellitus yet, is it less likely that an 
effect on beta cell function is secondary to decreased glucose toxicity (which in turn, 
could be a consequence of improved insulin sensitivity).
 In a double-blind, placebo-controlled, cross-over trial, participants were treated 
with anakinra or matching placebo subcutaneously, once daily for four weeks. 
Anakinra significantly decreased leukocyte counts and c-reactive protein levels. 
Treatment increased first phase insulin secretion as measured with a hyperglycemic 
clamp and improved the insulinogenic index. No effects were observed on insulin 
sensitivity, GLP-1 and glucagon. 
Together, the results of the last three chapters suggest that IL-1 blockade with 
anakinra has a modest effect on beta-cell function in patients with (pre-) diabetes. 
The effect on insulin sensitivity seems minimal in subjects with the metabolic 
syndrome, but appears promising in patients with chronic hyperglycemia-associated 
insulin resistance. Effects of anakinra on insulin sensitivity might partly be offset by 
local injection site reactions. 
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While research on IL-1F6 and IL-1F8 has focussed on psoriasis and mycobacterial 
infections, it has been demonstrated that other IL-1 cytokine members do have 
profound effects on metabolism and future investigations may reveal whether the 
same accounts for, especially, IL-1F6. While these are still early days for the new 
members of the IL-1 cytokine family, they seem to be important in the regulation of 
obesity induced inflammation hence modification of these cytokines may yield new 
avenues to target obesity induced inflammation and improve glycaemic control. For 
example has it recently been showed that IL-37 protects against obesity induced 
inflammation and insulin resistance. (21)
Interleukin-1
After the 2007 landmark trial showing positive effects of anakinra treatment on glycaemic 
control (22) many subsequent trials have tested IL-1(β) blockade in diabetes mellitus. 
 While we applied the IL-1 receptor antagonist anakinra, the actions of IL-1β can 
also be blocked by monoclonal antibodies, and this has been studied in large clinical 
trials. The results have been rather disappointing. Effects on glycaemic control have 
been modestly positive at best, (23-25) while others found no effect. (26, 27) Two 
trials that showed an improvement in glycemic control, reported a (non-significant) 
beneficial effect on insulin secretion. (23, 24) 
 One of the trials reporting no effect on glycaemic control, did report a non- 
significant improvement in HbA1c and postprandial glycaemia and a significant 
improvement in insulin secretion. (27) In one trial, anakinra or canakinumab were 
tested versus placebo in patients with recent onset type 1 diabetes mellitus, and did 
not report an improvement in C-peptide levels. (26) However, this trial was intended as 
an immune intervention trial in type 1 diabetes, with pathophysiological mechanisms 
likely to be different from the inflammatory activation in type 2 diabetes.
 Of all trials with IL-1β antibodies, two trials have fully focussed on patients with 
advanced diabetes mellitus and high HbA1c levels. (22, 23) It is remarkably that these 
trial report relatively large improvement in diabetes-related measurements. 
All other trials have included patients with well-controlled type 2 diabetes mellitus or 
patients with recent onset type 1 diabetes mellitus. 
 Thus, the effectiveness to improve glucose control in type 2 diabetes of IL-1β 
blockade strategies seems very limited and the initially reported positive findings 
have not been reproduced. This may be explained by a number of factors. First, it 
may be that the intervention does not work in relatively well-controlled patients. We 
found a clear, sustained effect in type 1 diabetes patients with marked chronic 
hyperglycemia. Hence, it would be of interest to perform a trial focussing on patients 
with high HbA1c levels or marked insulin resistance to elucidate potential effects of 
IL-1(β) blockade in this particular group of patients.
in humans. While this suggests that TLR-3 activation may have more profound effects 
in humans, we found in human fat tissue, that TLR-3 expression was neither correlated 
with BMI or HOMA-IR, nor with markers for adipocyte differentiation or adipose tissue 
inflammation. Noticeably, these results were generated using subcutaneous adipose 
tissue. It is not known whether the same holds true for the metabolically more active 
visceral depot. 
 Altogether, the function of TLR-3 in adipose tissue appears relatively small, but 
we cannot completely rule out a modest effect of TLR-3 on adipose tissue inflammation 
or insulin sensitivity. Based on the results of this study, it appears that TLR3 is present 
and active in adipose tissue yet its precise function remains unknown.   
 Another interesting question is whether TLR-3 is involved in beta-cell destruction 
in (type-1) diabetes mellitus. (9) It has been hypothesized that viruses are involved in 
the pathogenesis of beta-cell destruction in type-1 diabetes mellitus. TLR-3 expression in 
pancreatic islets is described in some cases of diabetes mellitus characterised by 
fulminant destruction of pancreatic beta-cell function. (10) In this thesis, we have not 
studied the role of TLR-3 in relation to beta-cell function. 
Interleukin-1 cytokine family
In the last years, the function of the many IL-1 cytokine family members have become 
more clear, mechanistic pathways have been unravelled and effects of many of the 
IL-1 family members on metabolic functions have been elucidated.  Just before the 
start of this research project it was revealed that IL-18 had significant effects on 
metabolism. Blocking IL-18 in mice resulted in hyperphagia, obesity and insulin 
resistance. (11) Prompted by this finding, other IL-1 family members have been 
studied extensively for their effects on metabolism. This thesis described the effects 
of IL-1F6 and IL-1F8 on adipocyte differentiation. (12) These cytokines are nowadays 
termed IL-36α and IL-36β respectively. (13)
 IL-36 cytokines are present in keratinocytes and other epithelial cell types and 
appear to be involved in the regulation of inflammatory responses in human psoriatic 
disease. (14-16) IL-36Ra is associated with a form of pustular psoriasis. (17) IL-36 is 
produced by epithelial and dendritic cells and activates dendritic cells to produce 
IL-12 and promotes survival, proliferation and IL-2 secretion of CD4+ T0-cells. This 
results in polarization of these naïve T-cells in an IL-2 dependent way to CD4+T1-cells 
resulting in interferon gamma mediated immune responses. (18, 19) Altogether, IL36 
appears to function as an early danger signal that activates and modulates the 
immune response. A recent study evaluated the effects of IL-36 on host defence in 
mycobacterial infection but found no difference in survival between IL-36 knockout 
mice and wild-type control mice. (20) It will be of interest to determine whether IL-36 
blocking strategies can have positive effects on severe inflammatory conditions, 
such as psoriasis, without affecting the immune response to mycobacterial infections.
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system, more research is needed to determine a phenotype/genotype most suited 
for anti-inflammatory therapy and to identify those patients that would benefit most 
from IL-1ra, or other anti-inflammatory treatment. Finally, the role of IL-1β in human 
(patho-) physiology might be less important then we think it is, although many in vitro 
and in vivo findings argue against this possibility. 
It is important to note that treatment with anakinra differs significantly from treatment 
with IL-1β blocking antibodies. Anakinra has a relatively low bioavailability necessitating 
daily injections. On the other side does anakinra block not only IL-1β but also IL-1α. 
The role of IL-1α on glycaemic control is completely unknown. The fact that IL-1α is 
primarily present intracellularly and IL-1 blocking drugs act extracellularly, suggests 
that an IL-1α mediated effect is less likely. On the other hand, IL-1α is known to reduce 
adipocyte differentiation and IL-1α levels are higher in obese mice, although 
mRNA-levels of IL-1α are lower. (30) Furthermore, IL-1α reduces insulin signalling in 
murine adipocytes. (31) Recently it has been shown that endogenous oil derived of 
human adipocytes recruits immune cells in an IL-1α dependent way. (32) Altogether 
it would it be interesting to test specific IL-1α antibodies or therapies effectively 
blocking both IL-1α and IL-1β, for example by applying the soluble decoy IL-1 receptor 
protein Rilonacept. 
 Alternative approaches to block excessive inflammatory responses by TNFα- 
antibodies, salsalates or a combination of anti-inflammatory strategies represent 
potentially interesting interventions, yet will need further study. 
Taken together, blocking IL-1β appears to have a positive, but small effect on 
glycaemic control in a subset of patients. Most likely, this effect is mediated by a 
moderate improvement in insulin secretion. Effects on insulin sensitivity are less 
clear, but, as we show in this thesis, may exist in subgroups. Future research efforts 
should focus on ways to identify the right intervention for the right patient. Clearly, 
further work is needed before anti-inflammatory therapies in general and IL-1β-blocking 
strategies in particular can be applied successfully in daily clinical practice.
 Second, anti-inflammatory interventions may not work in all patients, as enhanced 
inflammation and / or IL-1β may not underlie insulin resistance in all patients. Hence, 
another strategy would be to focus on individuals with a pro-inflammatory status that 
might be identified using circulating concentrations of C-reactive protein. This 
approach has been applied in the CANTOS-trial, which is using Canakinumab to 
reduce IL-1 mediated inflammation. (28) First reports on the effects of Canakinumab 
treatment in patients with diabetes and elevated CRP levels, however, did not yield 
clear beneficial effects on glucose control. (25) Similarly, it has been suggested that 
patients with lower IL-1RA levels, and thus a potentially higher pro-inflammatory 
status, would benefit more from anakinra treatment. (29) In our trials, we could not 
correlate the effectiveness of anakinra treatment with circulating IL-1RA levels, but the 
number of patients was relatively low. 
 Alternatively, other “host characteristics” such as genetic polymorphisms relevant for 
variations in the immune systems, might be important in determining the effectiveness 
of anti-IL1 therapy. While this possibility is likely given the complexity of the immune 
Table 1   Overview of trials testing IL-1β antibodies in diabetes mellitus.
Auteur (ref) Drug Subjects Main effects
Larsen (22) Anakinra 70 T2DM patients Glycemic control 
Insulin secretion 
Insulin sensitivity ≈
Cavelti-Weder 
(23)
Gevokizumab 98 T2DM patients Glycemic control 
Insulin secretion ≈(  n.s.)
Insulin sensitivity ≈
Sloan-Lancaster 
(24) 
LY2189102 106 T2DM patients Glycemic control 
Insulin secretion ≈ (  n.s.)
Insulin sensitivity ≈
Hensen (25) Canakinumab 551 T2DM patients Glycemic control ≈ (  n.s.)
Insulin secretion ≈
Insulin sensitivity ≈
Rissanen (27) Canakinumab 190 T2DM patients
54 Impaired glucose 
tolerance
Glycemic control ≈
Insulin secretion 
Insulin sensitivity ≈
Moran (26) Canakinumab/
Anakinra
69 Canakinumab/
placebo
69 Anakinra/placebo
recent onset T1DM 
patients 
Glycemic control ≈
Insulin secretion ≈
T1DM= type 1 diabetes mellitus, T2DM= type 2 diabetes mellitus, n.s.= non-significant. In grey trials 
testing IL-1β antagonism in type 1 diabetes mellitus.
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Nederlandse samenvatting
Diabetes mellitus  (suikerziekte) komt wereldwijd heel veel voor: in 2014 had 9% van 
de wereldbevolking diabetes mellitus. De verwachting is dat het aantal mensen met 
diabetes de komende jaren fors gaat toenemen. Dit is een groot probleem, onder 
andere omdat diabetes mellitus het risico op hart- en vaatziekten sterk verhoogt. 
Diabetes mellitus wordt gekenmerkt door chronisch verhoogde glucosewaarden 
(bloedsuikerwaarden). Er bestaan verschillende vormen van diabetes, het meest 
bekend zijn type 1 en type 2 diabetes. Type 1 diabetes ontstaat vaak op jonge leeftijd, 
wordt veroorzaakt door destructie van insulineproducerende cellen in de eilandjes 
van Langerhans en moet altijd worden behandeld met insuline. Insuline is essentieel 
voor normale glucosewaarden. Insuline zorgt ervoor dat glucose de lichaamscel in 
wordt getransporteerd. 
 Diabetes mellitus type 2 is veruit het meest voorkomend. Bij diabetes mellitus 
type 2 (ook wel ouderdomsdiabetes genoemd) is het belangrijkste probleem dat de 
gevoeligheid van de lichaamscellen voor de werking van insuline afneemt. Als de 
lichaamscellen minder gevoelig worden voor insuline, gaat de alvleesklier meer 
insuline produceren, zodat het bloedsuikergehalte in eerste instantie normaal blijft. In 
veel gevallen raakt de alvleesklier na verloop van tijd uitgeput, gelijktijdig neemt de 
insulinegevoeligheid verder af. Op dat moment stijgt de bloedsuikerwaarde en 
spreken we van diabetes mellitus.
 We spreken van gestoorde glucosetolerantie als de bloedsuikerspiegel na een 
maaltijd meer dan normaal stijgt, maar niet zodanig dat er sprake is van diabetes 
mellitus. Gestoorde glucosetolerantie is vaak een voorstadium van diabetes mellitus. 
Diabetes mellitus type 2 komt vaker voor bij overgewicht. Als het aantal mensen met 
overgewicht stijgt zal ook de prevalentie van diabetes mellitus stijgen. Om de 
prevalentie van diabetes mellitus te verminderen, is het meest voor de hand liggend 
om te streven naar het behandelen, of – nog beter – naar het voorkómen van 
overgewicht. Dit zou bijvoorbeeld bereikt kunnen worden door goede voorlichting, 
door ongezonde voeding duurder te maken, gezonde voeding te subsidiëren en door 
lichamelijke activiteit te bevorderen. Helaas is dit makkelijker gezegd dan gedaan. 
We leven immers in een maatschappij waarin (ongezond) voedsel altijd en overal 
beschikbaar is en waarin lichaamsbeweging steeds minder noodzakelijk is. Naast 
bovengenoemde maatregelen is het daarom ook belangrijk om de interactie tussen 
overgewicht en diabetes mellitus beter te begrijpen om zo mogelijk een meer gerichte 
behandeling te kunnen ontwikkelen.  
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 Toen we vervolgens muizen die geen TLR-3 tot expressie konden brengen, 
vergeleken met normale muizen bleek er echter geen verschil te zijn in lichaams-
gewicht, insulinegevoeligheid en ontstekingsniveau in het bloed. Ook bij mensen 
bleek er geen relatie tussen de expressie van TLR-3 in vetweefsel en het lichaams-
gewicht, ontsteking of insulinegevoeligheid te bestaan.  Al deze resultaten bij elkaar 
genomen moeten we concluderen dat TLR-3 veel tot expressie komt in het vetweefsel 
en ook functioneel actief is, maar nauwelijks effect lijkt te hebben op de stofwisseling. 
In het vervolg van dit proefschrift hebben we ons gefocust op de Interleukine (IL)-1 
familie. IL-1 is een boodschappermolecuul dat een belangrijke rol speelt in de li-
chaamsreactie op ontsteking. In geval van een ontsteking wordt IL-1 geproduceerd 
door afweercellen zoals macrofagen. Door de productie van IL-1 treden er in het 
lichaam verschillende reacties op die leiden tot een adequate afweerreactie. In de 
afgelopen decennia zijn er verschillende op IL-1 lijkende moleculen ontdekt. Samen 
vormen deze de IL-1 cytokinefamilie. Van verschillende leden van de IL-1 cytokine-
familie is bekend dat ze effect hebben op de stofwisseling.
 In  hoofdstuk 3 hebben we onderzocht of twee relatief nieuw ontdekte leden van 
de IL-1 familie, IL-1F6 en IL-1F8, aanwezig zijn in het vetweefsel en wat hun effect op 
vetcellen is. 
 IL-1F6 konden we, in tegenstelling tot IL-1F8, inderdaad aantonen in vetweefsel. 
Blootstelling van vetcellen aan IL-1F6 had tot gevolg dat de aanwezigheid van vet-
cel-stimulerende genen afnam, terwijl de aanwezigheid van pro-inflammatoire genen 
juist toenam. IL-1F8 stimuleerde de expressie van pro-inflammatoire genen. Met name 
IL-1F6 heeft een soort IL-1-achtig effect op vetcellen. 
In de tweede helft van dit proefschrift hebben we getest of blokkade van IL-1 effect 
heeft op insulinegevoeligheid en insulineproductie (beta-celfunctie). Anakinra is een 
in Nederland geregistreerd geneesmiddel dat wordt toegepast bij de behandeling 
van onder andere reumatoïde artritis. Het blokkeert de IL-1 receptor. In drie onder- 
zoeken hebben we verschillende patiëntengroepen, met nauwkeurig vastgestelde 
kenmerken op het gebied van insulinegevoeligheid en insulineproductie, behandeld 
met anakinra. Hierdoor waren we in staat om te bepalen wat het effect van IL-1 
blokkade is op insulineproductie en -gevoeligheid. 
In hoofdstuk 4 beschrijven we de resultaten van het onderzoek met anakinra bij 
personen met overgewicht en risicofactoren voor hart- en vaatziekten (metabool 
syndroom), maar zonder diabetes mellitus. Deze onderzoekspopulatie is insuline-
resistent, maar heeft geen verhoogde bloedsuikerwaarde en gebruikt dus ook geen 
medicijnen voor diabetes mellitus. Hierdoor is het makkelijker om te kijken naar de 
effecten van anakinra op insulinegevoeligheid en insulineproductie. We beoordeelden 
In dit proefschrift hebben we geprobeerd meer inzicht te krijgen in de relatie tussen 
overgewicht en diabetes mellitus. Het is een interessant gegeven dat de ene persoon 
met sterk overgewicht (obesitas) geen diabetes mellitus ontwikkelt, terwijl een ander 
zonder overgewicht juist wel diabetes mellitus type 2 krijgt. De relatie tussen 
overgewicht en diabetes mellitus type 2 is erg complex. Daarom hebben we hier 
gekeken naar de invloed van één specifieke factor, namelijk ontsteking, op het 
ontstaan van insulinetekort en insulineresistentie. 
Het was reeds bekend dat mensen met overgewicht gemiddeld hogere ontsteking-
swaarden in het bloed hebben dan slanke mensen. Verondersteld wordt dat dit het 
gevolg is van een chronische, milde ontstekingsreactie in het vetweefsel. Waarom 
deze ontstekingsreactie ontstaat, is niet geheel duidelijk. Eén hypothese is dat groei 
van de hoeveelheid en grootte van vetcellen leidt tot lokaal zuurstoftekort in het 
vetweefsel. Hierdoor gaan er vetcellen dood. Deze dode cellen brengen een ont-
stekingsreactie op gang die ervoor zorgt dat de dode cellen worden opgeruimd. Als 
we nu verder redeneren, zou het zo kunnen zijn dan deze ontsteking leidt tot 
verminderd functioneren van de overige vetcellen. Dit zou dan weer kunnen leiden tot 
een verminderde gevoeligheid van de vetcellen voor insuline. We spreken dan van 
insulineresistentie en dat kan vervolgens leiden tot diabetes mellitus type 2. 
In het eerste deel van dit proefschrift hebben we onderzoek gedaan naar het effect 
van verschillende componenten van de ontstekingsreactie op de vetcellen en op de 
werking van insuline. In de tweede helft van dit proefschrift hebben we geprobeerd 
om de ontstekingsreactie te remmen om vervolgens te kijken wat het gevolg hiervan 
is voor zowel insulinegevoeligheid als insulineproductie.  
  
Een ontstekingsreactie ontstaat als het afweersysteem van ons lichaam een 
moleculair patroon herkent als mogelijk gevaarlijk. Dit kan zowel een lichaamsvreem-
de stof (bijvoorbeeld een bacterie) als een lichaamseigen stof (die zich op een 
ongebruikelijk plek bevindt) zijn. 
 Receptoren  die potentieel gevaarlijke moleculen kunnen binden worden  ‘Pathogen 
recognition receptors’ (PRR’s) genoemd. De meest bekende groep van PRR’s zijn de 
Toll-Like Receptors (TLR’s). In hoofdstuk 2 hebben we gekeken naar het voorkomen 
van TLR’s in het vetweefsel en hun aanwezigheid in de verschillende componenten 
van het vetweefsel. TLR-3 en TLR-5 hadden een opvallend verspreidingspatroon. 
Ze bleken met name voor te komen in de vetcelfractie, dit in tegenstelling tot de 
overige TLR’s die met name voorkwamen in de niet-vetcelfractie.  Vervolgens hebben 
we vastgesteld dat TLR-3 functioneel actief is. Door TLR-3 te stimuleren bleken de 
vetcellen meer pro-inflammatoire genen (bijvoorbeeld IL-8 en MCP-1) en minder 
 vetcelstimulerende genen (PPAR-gamma en adiponectine) tot expressie te brengen. 
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een maaltijd meer dan normaal. Dit is het gevolg van verminderde insulineproductie.
Deze studie had dezelfde opzet als het eerder in hoofdstuk 4 beschreven onderzoek. 
Alle proefpersonen ondergingen een hyperglycemische clamp vóór de eerste en na 
iedere onderzoeksperiode. Een hyperglycemische clamp is de meest nauwkeurige 
methode voor het bepalen van de insulineproductiecapaciteit. Anakinra verlaagde 
opnieuw de ontstekingswaarden in het bloed. De insulineproductie tijdens de eerste 
fase van de clamp verbeterde. Bij dit onderzoek werd geen verbetering gezien in 
 insulinegevoeligheid en ook niet in andere parameters voor diabetes regulatie. 
De drie onderzoeken naar het effect  van IL-1 blokkade met anakinra laten zien dat 
anakinra enige verbetering van de beta-celfunctie geeft. De effecten op insuline-
gevoeligheid zijn minimaal bij patiënten met het metabool syndroom, maar meer 
uitgesproken bij patiënten met chronisch verhoogde bloedsuikerwaarden. De effecten 
van anakinra op insulinegevoeligheid worden mogelijk negatief beïnvloed door lokale 
ontstekingsreacties ten gevolge van anakinra injecties. 
 Alles bijeen genomen zou het remmen van ontsteking in het algemeen en het 
blokkeren van de werking van IL-1 in het bijzonder bij sommige patiënten nuttig 
kunnen zijn, maar het effect is beperkt en er zijn ook patiënten bij wie geen enkel 
effect optreedt. 
Toekomstige onderzoeken moeten er daarom op gericht zijn om de juiste (anti- 
inflammatoire) behandeling te vinden voor de juiste patiënt. Voor het overige is het 
van belang om te onderzoeken wat het effect van anti-inflammatoire behandeling op 
hart- en vaatziekten is. Er zijn namelijk ook sterke aanwijzingen dat verhoogde 
 ontstekingswaarden gerelateerd zijn aan een verhoogd risico op hart- en vaatziekten. 
Kortom de relatie tussen diabetes mellitus en ontsteking is ingewikkeld, maar biedt 
zeker aanknopingspunten voor toekomstige behandelingen. 
de insulinegevoeligheid met behulp van een euglycemische hyperinsulinemisch 
clamp, de meest gevoelige onderzoeksmethode voor het meten van insulinegevoe-
ligheid. Hiernaast deden we een orale glucose tolerantietest, met deze test kan een 
indruk worden gekregen van de insulineproductie.    
 De proefpersonen werden gedurende vier weken behandeld met anakinra of 
placebo (nepmedicijn), daarna volgde een tweede behandelperiode met nu de 
andere vorm van behandeling. Vóór de eerste en na iedere onderzoeksperiode 
deden we bovengenoemde onderzoeken, en we namen een klein beetje weefsel af 
uit het onderhuids buikvet. Anakinra bleek geen invloed te hebben op de insuline-
gevoeligheid, maar verbeterde wel de insulineproductie. 
 Veel proefpersonen hadden last van een ontstekingsreactie op de plaats waar 
anakinra werd ingespoten. Dit is een bekende bijwerking. Het bleek dat de sterkte 
van de ontstekingsreactie in het vetweefsel correleerde met de verandering in 
insuline gevoeligheid. Het zou dus zo kunnen zijn dat een mogelijk positief effect van 
anakinra op de insulinegevoeligheid te niet wordt gedaan door de lokale ontstekings-
reactie. Een andere mogelijkheid is dat een effect van anakinra op insulinegevoelig-
heid minder sterk is bij normale bloedsuikerwaarden. 
In hoofdstuk 5 is vervolgonderzoek gedaan naar de effecten van anakinra op 
insuline gevoeligheid bij mensen met hoge glucosewaarden. Voor dit onderzoek hebben 
we patiënten met lang bestaande diabetes mellitus type 1, overgewicht en relatief 
matige diabetesregulatie geselecteerd. Deze patiënten hebben geen resterende 
 insulineproductie, zodat iedere verbetering van de bloedsuikerregulatie het gevolg 
moet zijn van betere insulinegevoeligheid. Deze patiënten kregen een relatief lage 
dosering anakinra gedurende een week. Hierdoor waren er minder problemen met 
lokale ontstekingsreacties. 
 Na een week behandeling met anakinra verbeterde de insulinegevoeligheid, 
 bloedsuikerwaarden en verminderde de insulinebehoefte. Dit effect was nog steeds 
zichtbaar vier weken na het einde van de behandeling met anakinra.  Deze resultaten 
suggereren dat het blokkeren van IL-1 bij sommige patiënten nuttig kan zijn. Aangezien 
dit onderzoek niet geblindeerd was en geen controlegroep bevatte kan een 
studie-effect (effect puur door het feit dat patiënten vaker worden gecontroleerd en 
zichzelf controleren doordat ze deelnemen aan een onderzoek)  als verklaring voor 
de verbetering niet geheel worden uitgesloten. Het feit dat de verbetering in insuline-
gevoeligheid sterk gecorreleerd was met de verbetering in ontstekingsgraad maakt 
dit minder waarschijnlijk. 
Ten slotte hebben we in hoofdstuk 6 de effecten van anakinra op de insulineproductie 
onderzocht. Voor dit onderzoek werden proefpersonen geselecteerd met een 
verminderde glucosetolerantie. Bij deze patiënten stijgt de bloedsuikerwaarde na 
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Allereerst wil ik alle vrijwilligers bedanken voor hun bereidwilligheid om mee te werken 
aan dit onderzoek. Enigszins tot mijn verbazing hebben jullie altijd zonder morren en 
met een goed humeur meegewerkt aan clamps, vetbiopten en andere onderzoeken 
om de inzichten in en behandeling van diabetes mellitus te verbeteren. Alhoewel dit 
een kleine stap is in het grote geheel zijn we samen toch een stukje verder gekomen.
Professor Tack, beste Cees, in 2008 zijn we dit project gestart. Ik wilde graag onderzoek 
doen binnen de endocrinologie en jij had een onderzoek lopen naar de invloed van 
ontsteking op diabetes mellitus. Jij bood me de mogelijkheid om gedurende drie jaar 
fulltime wetenschappelijk onderzoek te gaan doen. Hoewel je het uiteindelijk tot vier 
jaar wist te rekken, had ik beduidend meer tijd nodig om tot dit geheel te komen. 
Waarschijnlijk heeft je dit wel eens teleurgesteld. Ik waardeer het zeer dat je er in bent 
geslaagd dit niet teveel negatief te laten doorschemeren en mij gelijktijdig toch 
positief bent blijven motiveren en stimuleren om dit onderzoek af te ronden.
Professor Netea, beste Mihai, jij bent iemand die in staat is om de waarde te zien 
van onverwachte uitkomsten en je weet deze zo te interpreteren dat dit uiteindelijk 
leidt tot nog mooiere onderzoeksprojecten. Dit vermogen heeft al vaak geleid tot 
opzienbarende bevindingen. Ook in dit project was je weer van onschatbare waarde. 
Tijdens de wekelijkse onderzoeksbijeenkomsten wist je me altijd weer te motiveren. 
Beste Rinke, ik kan me nog herinneren dat je je data liet zien tijdens mijn eerste 
bijeenkomst met Prof. Dr. Tack. Ik had verteld dat ik al wel het een en ander had 
gelezen over dit onderwerp, echter na deze presentatie was het mij duidelijk dat ik er 
eigenlijk nog niets van wist. Geleidelijk aan is dit weliswaar bij getrokken, maar het is 
me altijd blijven verbazen hoe snel jij in staat bent nieuwe data te interpreteren en 
vervolgens de beste vervolgstappen voor te stellen. Mijn werkzaamheden in het lab 
waren zeker op niets uit gelopen zonder jouw praktische adviezen. Dank ook voor 
alle hulp bij het schrijven van de artikelen. Tenslotte heb ik de gezelligheid en de 
koffie in de buitenhoek zeer gewaardeerd. 
Beste Prof. dr. Joosten, Prof. dr. Pickkers, Prof. dr. Donath, dank dat jullie wilden 
plaatsnemen in de promotiecommissie. Dank ook voor de kritische beschouwing en 
goedkeuring van het proefschrift. 
Beste Anneke, Heidi, Helga, Trees, Liesbeth, Johanna, Ineke, Cor en Magda, samen 
vormen jullie de harde kern van het laboratorium Experimentele Interne Geneeskunde. 
Jullie hebben al vele promovendi voorbij zien komen. Ik hoop dat jullie mij herinneren 
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Prof. Dr. Hermus, beste Ad bedankt voor de mogelijkheid die je hebt geboden om me 
te specialiseren tot endocrinoloog. 
Beste Pieter, Rinke, Janna, Tim, Henri, Heleen, Suzanne, Mark, Sanne, Duby, Peter, 
Theo. Dank voor al jullie hulp bij experimenten in het lab (ik had vaak hulp nodig als 
clinicus…),bij het schrijven van artikelen, het maken van figuren en statistische 
analyses. Ook bedankt voor de minder wetenschappelijke, maar minstens even 
belangrijke ondersteuning (koffie, praatjes, fietstocht, bioscoopbezoek en nog veel 
meer). 
Beste Annenienke, Henri, Nike en Romana samen met Ad hebben jullie gezorgd voor 
stabiliteit binnen de endocrinologie. Jullie hebben me altijd, zonder mokken, geholpen 
bij alle klinische vragen die ik had. Iedere poli werd uitgebreid besproken en bij meer 
complexe problematiek boden jullie altijd een helpende hand. Dank zij jullie voel ik 
me klaar om als endocrinoloog de wijde wereld in te trekken. 
Beste Gerald, Lammy, Bernadet, Petra en Bastiaan, bedankt voor jullie laagdrempelige 
benaderbaarheid. Gerald speciaal bedankt voor het altijd weer geduldig doornemen 
van mijn poli. Je adviezen waren bijzonder bruikbaar en praktisch.  
Beste Engelien, Hanneke, Irma, Kim, Lonneke, Marlies, Pascal, Petri, Pleun en Sandra 
bedankt voor de prettige samenwerking tijdens de endocrinologie opleiding. We 
hebben samen hard gewerkt, veel geleerd, af en toe geklaagd, maar vooral een 
stevige basis gelegd voor een mooie toekomst als endocrinoloog.
Beste internisten van het CWZ bedankt dat ik bij jullie de eerste stapjes op weg naar 
het internistendom mocht zetten. Ik heb mijn tijd in het CWZ altijd als zeer prettig en 
waardevol ervaren. Beste Ton en Mark bedankt voor de prima opleiding. Beste Sven, 
Mark (dyslipidemie? -> DD hypothyreoidie)  en Johan (cyclische Cushing) bedankt 
voor deze en vele andere eerste lessen binnen de endocrinologie! 
Bästa kollegor vid Oskarshamns medicinkliniken. Tillsammans är vi stora och är vi 
starka! Sista delen av min bok har jag skrivit i Sverige. Det var inte så lätt, men det 
gick bra med ert stöd.  
Beste vrienden. Mannen van de ‘mannenavond’, wat heerlijk om af en toe met jullie 
biertjes te drinken en bij te praten. De mannenavond is een van de weinige zaken die 
ik echt mis nu ik hier in Zweden woon. Ik blijf hopen op een mannenavond/weekend 
in Oskarshamn! 
als een prettige collega en dat jullie mijn ietwat magere laboratoriumvaardigheden 
door de vingers willen zien. Bedankt voor de praktische adviezen, alle goede hulp en 
de vele gezellige momenten. 
Beste Karin, Anja en Mariëlle, drijvende krachten binnen de oude afdeling klinische 
fysiologie. Jullie hebben mij enorm geholpen met alle logistiek rond de clamps en 
vetbiopten. Tevens bedankt voor alle deskundige hulp bij niet functionerende infusen 
of apparaten (ik denk bijvoorbeeld aan handwarmers en glucose analysers…) en bij 
het bestellen van alle benodigde materialen. 
Beste Pleun, samen hebben we het klinische deel van dit onderzoek verricht. Het was 
erg prettig om met jou als collega samen te werken, zowel in het onderzoek als later 
bij de endocrinologie. Jouw nauwkeurigheid en gedrevenheid hebben in belangrijke 
mate bijgedragen aan de kwaliteit van dit onderzoek. Ik wens je een mooie verdere 
carrière in het Maxima Medisch Centrum, maar vooral ook het allerbeste samen met 
je gezin. 
Beste Henry, samen hebben we de vetbiopten opgezet in Nijmegen. Bedankt voor 
de zeer plezierige samenwerking. Bedankt ook voor de gezelligheid in de buitenhoek 
(om een paar aspecten te noemen: New Kids, imitaties van slechte actiefilms en heel 
veel cola (light) + koffie). 
Beste Pieter, bedankt dat je er altijd bent als vriend. Zelfs in Zweden ben je me komen 
opzoeken. Bedankt ook voor de gezellige samenwerking in de buitenhoek. Met jou 
als paranimf aan mijn zijde kan het bijna niet meer mis gaan. 
Beste Marcel, ook jij bedankt dat je er altijd bent als vriend. Al lange tijd op afstand, 
maar toch weet je altijd weer een moment vrij te maken voor een berichtje, telefoontje 
of bezoekje. Zowel in het Nijmeegse als in het Zweedse heb je me weten te vinden. 
Bedankt dat jij vandaag aan mijn zijde staat. 
Prof. Dr. De Graaf, Prof. Dr. Van der Meer en Prof. Dr. Smit, beste Jacqueline, Jos en 
Jan, opleiders interne geneeskunde van het Radboud UMC. Ik ben trots en blij dat ik 
mijn opleiding interne geneeskunde heb kunnen en mogen doen in het Nijmeegse. 
Samen wisten jullie een goed en veilig opleidingsklimaat te creëren. Ik ben er, geloof 
ik, zonder al te grote hobbels doorheen gerold, maar zonder de omstandigheden die 
jullie hebben weten te creëren was dit onmogelijk geweest. Jacqueline een speciaal 
woord van dank voor het speciale afscheidsmoment wat je voor mij op poten hebt 
gezet. Ik voelde me echt gewaardeerd! 
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Beste ‘draaiende dokters’: ieder jaar één keer afzien in de Limburgse heuvels, vooraf 
en nadien perfecte verzorging in huize Saris. Ieder jaar weer dezelfde grote verhalen, 
tussensprints van Marcel en Kasper, drinken vanaf de start en nog veel meer 
‘tradities’. In een woord: fantastisch. Hopelijk laten we het niet versloffen nu we wat 
verder van elkaar zijn gaan wonen! 
Beste Boston-mannen, samen hebben we een heerlijke tijd gehad in Boston. De tijd 
vliegt maar ons goede contact is gelukkig blijven bestaan. 
Lieve papa en mama, bedankt voor het veilige en betrokken thuis wat jullie altijd voor 
mij zijn geweest en ook altijd zullen blijven. De bezoekjes aan het Zijtaartse zijn altijd 
relaxed en de verzorging is super. Bedankt voor al jullie ondersteuning, praktisch 
bijvoorbeeld als oppas of voor klusjes in huis of tuin, maar zeker ook voor even een 
goed gesprek! Ik heb er bewondering voor hoe jullie er altijd in geslaagd zijn om jullie 
aandacht te verdelen over jullie kinderen, ook als het met een van ons wat minder 
ging, verloren jullie de anderen nooit uit het oog.
Beste Anke en Marjan, lieve zussen, altijd als het nodig is, kunnen we terugvallen op 
elkaar. Dat maakt ons samen een hecht gezin en zorgt ervoor dat we er altijd weer 
boven op komen. Lieve Marjan ik hoop dat het nog lang zo goed mag gaan met jou 
als de laatste tijd. Je hebt het verdiend. Lieve Anke terwijl jouw leven op zijn kop staat, 
blijf jij positief in het leven staan en bouw je aan de toekomst. Zet ‘m op! 
Lieve Maaike, vaak heb je me gezegd ‘zonder mij was dat boekje van je veel eerder 
af geweest’. Je had natuurlijk weer eens gelijk. Echter heb je me ook aangemoedigd 
om door te zetten. Bovendien zonder jou zou mijn leven een stuk minder interessant 
zijn. Zonder jou had ik geen drie prachtige kinderen. MET jou is het leven leuk! 
Bedankt dat jij ervoor zorgt dat ik niet uit het oog verlies wat echt belangrijk is in 
het leven. 
Lieve Helle, Tobias en Voske, hier is dan papa’s boekje over suikerziekte. Dit boekje 
mag dan misschien ‘maar zo dun?!’ zijn, voor mij is dit boekje ZO groot. Laten we nu 
samen wat leuks gaan ondernemen. Ik ben trots op jullie.  
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Curriculum vitae
Edwin Josef Petrus van Asseldonk werd geboren op 18 maart 1980 in Zijtaart 
(gemeente Veghel). Hij voltooide zijn vwo-opleiding aan het Zwijssen College te 
Veghel. In 1998 begon hij met zijn studie geneeskunde aan de Radboud Universiteit 
Nijmegen (destijds Katholieke Universiteit Nijmegen). Tijdens zijn studie was hij twee 
jaar als bestuurslid actief binnen de Medische Faculteits Vereniging Nijmegen 
(MFVN). Edwin behaalde zijn doctoraalexamen in 2003. Tijdens zijn coschappen 
verrichtte hij wetenschappelijk onderzoek bij de afdeling Nefrologie van het Brigham 
and Women’s hospital in Boston, USA (Prof. dr. J.V. Bonventre). Hier deed hij 
onderzoek naar de functie van het eiwit Kidney Injury Molecule 1. 
 In 2005 behaalde hij zijn artsexamen en begon hij zijn opleiding tot internist aan 
de afdeling Interne Geneeskunde van het Radboud UMC te Nijmegen (opleiders 
Prof. dr. J.W.M. van der Meer, Prof. dr. J. de Graaf en Prof. dr. J.W.A. Smit). Tussen 
2005 en 2008 was hij voor het perifere deel van zijn opleiding werkzaam in het 
Canisius Wilhelmina Ziekenhuis te Nijmegen (opleiders Dr. A.S.M. Dofferhoff en 
Dr. M.J.T.M. Mol). Tussen 2008 en 2012 onderbrak hij zijn opleiding tot internist voor 
het doen van onderzoek naar de effecten van obesitas-geïnduceerde ontsteking op 
diabetes mellitus, wat uiteindelijk heeft geleid tot dit proefschrift. In 2012 vervolgde 
Edwin zijn opleiding tot internist in het Radboud UMC en startte hij de differentiatie tot 
endocrinoloog (opleider Prof. dr. A.R.M.M. Hermus), welke hij afrondde in september 
2014. 
 Vanaf januari 2015 is hij werkzaam als internist-endocrinoloog in Oskarshamn, 
Zweden. 
 Edwin woont samen met Maaike en samen hebben zij drie kinderen; Helle, Tobias 
en Voske.

